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Abstract
This thesis is divided into three main sections. The first chapter contains a brief review of 
nitrogen heterocyclic chemistry. The second chapter reports the results and their 
discussion of new heterocyclic chemistry, and the experimental details are provided in the 
fourth chapter.
The first part of chapter two contains the results and discussion related to the synthesis of 
the revised structure of the natural product acremolin. The second part of chapter two 
describes the synthesis of s-triazine derivatives starting from cyanuric fluoride or chloride., 
while the third part of this chapter reports advances in the synthesis of an EGFR inhibitor.
An initial attempt to prepare the revised structure of acremolin, compound 52, was 
undertaken. During this time, the first total synthesis of the desired structure was reported, 
so then work continued with an alternative synthetic route. The imidazopurine core was 
disconnected into two separate imidazole precursors 61 and 62. These two compounds 
were both successfully synthesized and isolated, but the yields were very poor, and the 
coupling reaction between these two precursors could not be achieved. We also prepared 
two analogues of the revised structure of acremolin, 68 and 69 as potential biologically 
active compounds. Three analogues of the imidazole precursors 70-72 were also prepared 
in order to allow synthesise of further analogues in the future.
In research on biologically active triazines, three mono-aryl, two di-aryl and one tri-aryl 
substituted s-triazines, compounds of interest as potential anticancer agents, were 
successfully synthesised. In addition, a number of commercially available primary (e.g. 
cyclopentylamine) and secondary (e.g. morpholine) amines were also attached to the s-
triazines, giving six mono-amino, six mono-aryl-mono-amino, two di-amino and two mono-
aryl-di-amino s-triazines. A number of these compounds are currently undergoing 
screening for biological activity.
In a further development of nitrogen heterocyclic chemistry, three N-2,3,5,6-tetra-4-
pyridinamine analogues 96, 103 and 104 as potential kinase inhibitors were prepared by 
SNAr reactions of perfluoroarenes. However, the desired substitution reactions at 
position-2 proved difficult and were unsuccessful. The amine moieties were then modified 
with either 4-toluenesulfonyl or propionic anhydride, giving more acidic secondary amides 
105, 106, 108 and 109. These modified compounds were only able to replace the fluoride 
at position-4 of the fluoropyridine ring in base catalysed SNAr reactions. 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Chapter 1: Introduction
Section 1: Introduction to Biologically Important Nitrogen  
Hetereocycles
1.1 Brief overview of deoxyribonucleic acid (DNA)
Deoxyribonucleic acid (DNA) is a polymer molecule, often consisting of many thousands or 
millions of monomer building blocks. The monomer units of DNA are nucleotides, and the 
polymer is known as a "polynucleotide." Each nucleotide consists of a 5-carbon sugar 
(deoxyribose), a nitrogen containing heterocyclic (base) attached to the sugar, and a 
phosphate group. There are four different types of nucleotides, adenine (A), guanine (G), 
cytosine (C) and thymine (T) found in DNA, differing only in the nitrogenous base.
Adenine 1 and guanine 2 are purines (Figure 1-1). Purines are the larger of the two types 
of bases found in DNA and consist of an imidazole ring fused to a pyrimidine ring. The 9 
atoms that make up the fused rings (5 carbon, 4 nitrogen) are numbered 1-9. All ring 
atoms lie in the same plane.
                                    
Figure 1-1. Adenine 1 and guanine 2.
Cytosine 3 and thymine 4 are pyrimidines (Figure 1-2). The 6 atoms (4 carbon, 2 nitrogen) 
are numbered 1-6. Like purines, all pyrimidine ring atoms lie in the same plane.
                                           
Figure 1-2. Cytosine 3 and thymine 4.
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The deoxyribose sugar 5 of the DNA backbone has 5 carbons and 3 oxygens (Figure 1-3). 
The carbon atoms are numbered 1', 2', 3', 4’ and 5' to distinguish from the numbering of 
the atoms of the purine and pyrmidine rings. The hydroxyl groups on the 5'- and 3'- 
carbons link to the phosphate groups to form the DNA backbone. Deoxyribose lacks a 
hydroxyl group at the 2'-position when compared to ribose, the sugar component of RNA.
 
Figure 1-3. The deoxyribose sugar 5 in DNA
DNA is a normally double stranded macromolecule. Two polynucleotide chains, held 
together by weak thermodynamic forces (hydrogen bonding), form a DNA molecule 
(Figure 1-4).
 
Figure 1-4. Two polynucleotide chains of DNA.
Within the DNA double helix, A forms 2 hydrogen bonds with T on the opposite strand, and 
G forms 3 hyrdorgen bonds with C on the opposite strand. dA-dT and dG-dC base pairs 
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are the same length, and occupy the same space within a DNA double helix. Therefore the 
DNA molecule has a uniform diameter.[1]
1.2 Historical overview of purines
The purine structure 6 is a common and important nitrogen-containing heterocycle in 
nature.[2] Purine bases, such as adenine 1 and guanine 2, their corresponding 
nucleosides, adenosine 7 and guanosine 8 and their metabolic products, the nucleoside 
inosine and the bases hypoxanthine 9 and xanthine 10, as well as purine nucleotides, 
such as adenosine 5' triphosphate (ATP), adenosine 5' diphosphate (ADP), adenosine 5' 
monophoshate (AMP), guanosine 5' triphosphate (GTP), guanosine 5' diphosphate (GDP) 
and guanosine 5' monophosphate (GMP), are ubiquitous molecules found within the cells 
of animals and plants (e.g. anchovies, brains, kidneys, liver, sardines, sweetbreads).[3]
 
 
 
Figure 1-5. Purine-base structures in nature.
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Purine bases and their pyrimidine counterparts are the building blocks of the nucleic acids 
that form deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). ATP is considered the 
universal cellular energy currency, it and other purine nucleotides and nucleosides are 
involved in biochemical pathways and energy transfer within the cell. Cyclic nucleotides 
such as adenosine 3’,5'-cylic monophosphate (cAMP) and guanosine 3’,5'-cylic 
monophosphate (cGMP) act as important intracellular second messenger molecules 
during signal transduction.
Although purines have mainly been traditionally viewed as having only intracellular roles, 
about 90 years ago Drury and Szent-Gyorgyi (1929) discovered that extracellular 
adenosine is a hormone released by the heart during ischemia. Over the last 30 years, 
however, the roles of adenosine and ATP as neurotransmitters and neuromodulators in the 
central, peripheral and enteric nervous systems have been elucidated.[4] Specific receptors 
for ATP[5] and adenosine[6] have now been identified. Outside the nervous system, 
adenosine and ATP were found to act not only as neurotransmitters, but also as hormones 
with ‘trophic’ roles. Trophic substances affect the structure, development, and integrity of a 
target cell or tissue over a longer time course than the milliseconds to seconds involved in 
neurotransmission. Trophic effects include the plastic changes involved in memory and 
learning, sprouting of nerve processes, neuroprotection against noxious stimuli and even 
regulation of cell number through stimulation of apoptosis (programmed cell death).
Moreover, such trophic signaling by extracellular purines is not limited to mammals; rather 
it is phylogenetically ancient and widespread in the plant and animal kingdoms.[7] For 
example, external GTP alters both the motility and membrane depolarization in the ciliated 
protist, Paramecium tetrauelia.[8]
In animals, signaling by extracellular purines has also been implicated in the control of a 
wide variety of physiological processes. Extracellular purinergic receptors have been 
located on numerous animal cell types[9] and their activation affects, for example, sperm 
motility, fertilization, embryo- genesis and organogenesis.[10] In mammalian cells, purines 
regulate vascular smooth muscle tone, cardiac muscle, platelet aggregation, 
gastrointestinal mobility, respiratory and renal function.[11]
  / 4 156
1.3 A brief introduction of purine based compounds
Purine is a privileged heterocyclic nucleus which exists in the chemical architecture of 
various bioactive compounds.[12] The purine nucleus has appeared as an important 
pharmacophore interacting with the synthesis, functions of nucleic acids and enzymes and 
is one of the most widely used heterocycles in the development of protein kinase 
inhibitors. The introduction of substituents on the 2, 6 and 9 positions of the purine ring is 
anticipated to yield compounds with enhanced binding affinity and selectivity toward 
kinases.[13] Purine based protein kinase inhibitors in pre-clinical/clinical trials are shown in 
Figure 1-6. 
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 
Figure 1-6. Purine based protein kinase inhibitors in pre-clinical/clinical trials.
A number of purine isostere core based drugs are also available in the market (Figure 
1-7), including temozolomide used for the chemotherapeutic treatment of brain cancer[14]; 
8-azaguanine[15] and forodesine[16] used for the treatment of leukemia; sildenafil and 
vardenafil,[17] PDE5 inhibitors, are used for the treatment of erectile dysfunction.
 
 
Figure 1-7. Therapeutic agents based on isosteric purine skeletons.
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isosteres of purine, pyrazolo[1,5-a][1,3,5]triazines (5-aza-9-deazapurines 11) and 1,2,4-
triazolo[1,5-a][1,3,5]triazines (5-azapurines 12)(Figure 1-8).[18,19] This group of 
azolo[1,3,5]triazine systems has a nitrogen atom in the position 5 of the purine ring and 
therefore can be generally categorized as 5-aza-isosteres of purine.
 
Figure 1-8. 1,3,5-Triazine-based purine-like scaffolds
Yang and co-workers performed a virtual screening followed by kinase inhibitory assays 
against a library of known kinase inhibitors. Among the tested compounds, N-(4-(4-
methylpiperazin-1-yl)phenyl)-N-phenyl-9H-purine-2,8-diamine 13 exhibited ability to inhibit 
both EGFR-activating and resistance mutations. After the structure was modified at the 
N-9 position of the purine, and with the phenyl ring of the 2-anilino group and the phenyl 
ring of the 8-anilino group, a series of novel 2,8-dianilinopurine derivatives were 
synthesized and tested for bioactivity. As a result, compound 14 generated the most anti-
tumor activity both in-vitro and in-vivo.[20]
 
Figure 1-9. 2,8-diamino purine analogs as reversible tyrosine kinase inhibitors. Reagents 
and conditions: (a) MeOH, 10% Pd/C, H2, 60 ˚C, 5 h, 48%. 
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Virta et al. synthesized four derivatives of a nucleoside base analogue, 2,6-diaminopurine, 
with an additional five-membered ring fused to the base moiety (Scheme 1-1).[21]
The exocyclic DNA adducts with an additional five-membered ring fused to the base 
moiety can be used as models to investigate what may be happening detrimentally on the 
bimolecular scale.[21] Virta et al. synthesized four derivatives of a nucleoside base 
analogue, 2,6-diaminopurine, with an additional five-membered ring fused to the base 
moiety (Scheme 1-1).[22]
 
Scheme 1-1. Reagents and conditions: (a) chloroacetaldehyde (ClCH2CHO), water/DMF, 
pH 4–5, 80 ˚C, 24 h.
Cyclic nucleosides play significant role for antiviral reagents, and they usually exist in 
biological metabolites[23] and synthetic intermediates.[24] Meng and co-workers synthesized 
multi-fused rings via intramolecular double C-H activation in purines and benzimidazole 
structures. (Scheme 1-10).[25]  A palladium catalyst was employed under acidic conditions 
and double C-H cyclization was proceeded. 
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Figure 1-10. Strategies for the synthesis of N-fused heterocycles. Where n=1,2,3. 
Reagents and conditions: (a) Pd(OAc)2 as catalyst, silver acetate, acetic acid, 110 ˚C, 36 
h.
1.4 Background to acremolin
Marine microorganisms, particularly actinomycete bacteria and fungi, are an important 
source of antibacterial, anti-algal and anti-larval compounds, which can potentially be used 
for biotechnological applications. Hundreds of novel compounds are isolated from these 
organisms annually.
Shin and co-workers isolated a strain of Acremonium strictum which was obtained from an 
unidentified Choristida sponge collected from Korean waters.[26] A novel modified base 
acremolin, was isolated as a white amorphous solid after continuous work with this strain 
using diverse culture media which exhibited weak cytotoxicity against A549 cell line.
After analysis of the white amorphous solid with HR-FAB-MS the molecular formula was 
identified as C11H13N5O. In addition, IR, 1H NMR and 13C NMR spectroscopic experiments 
were performed, and the structure of acremolin was firstly proposed as 22. Shin and co-
workers emphasized the acremolin was first example of a 1H-azirine metabolite, which 
was unprecedented among natural products.
1H-azirines and 2H-azirines are heterocyles have different number of electrons in the π 
system as shown in Figure 1-11. 2H-azirines has been found in a few natural products.[27] 
In contrast, only 5 examples of short-lived antiaromatic heterocycles, 1H-azirines, have 
been photochemically generated and identified by IR spectroscopy at very low 
temperatures.[28]
 
Figure 1-11. 1H-azirines (left) and 2H-azirines (right)
Klaus raised doubts about the structure 22 due to the acremolin being isolated at room 
temperature, which is contradictory to all previous experimental and theoretical results.[29]
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Then he omitted the 1H-azirine moiety and introduced a second fused five-membered 
cyclic system. After comparing the 1H and 13C NMR data with a published compound 1H-
imidazo[2,1-b]-purine-4(5H)-one (Figure 1-12)[30], the structure was reoriented to an 
isomeric ring system for acremolin, namely a substituted N2,3-ethenoguanine, which is 
consistent with all spectroscopic data 23 (Figure 1-13).
 
Figure 1-12. 1H-imidazo[2,1-b]-purine-4(5H)-one
 
Figure 1-13. Acremolin 22 and the revised structure 23
1H-azirines still only exist as short-lived intermediates and cannot be isolated from natural 
products at room temperatures. In this thesis, we aim to synthesis the revised structure of 
acremolin 23 and compare the spectroscope data with the published by Shin and co-
workers. 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Section 2: Introduction to s-triazine and its derivatives
1.5 Introduction to the chemistry of s-triazine and its derivatives
This research involves synthesis of new drug candidates based on triazines and the 
chemistry of this ring and current drugs containing a triazine ring are reviewed here.
The design, synthesis and evaluation of molecules with potential human therapeutic 
values, remains one of the main objectives of organic and medicinal chemistry. During the 
past decades, combinatorial chemistry has provided access to chemical libraries based on 
privileged heterocyclic motifs with utility in medicinal chemistry.[31] Synthesis of nitrogen 
containing heterocyclic compounds has been attracting increasing interest because of their 
utility for various biological receptors with a high degree of binding affinity.
Triazines are six-membered aromatic heterocycles comprised of three carbon and three 
nitrogen atoms. The three isomers shown below in Figure 1-13
 are 1,2,3-triazine 24, 1,2,4-triazine 25, and 1,3,5-triazine 26.
 
Figure 1-13. Triazine isomers
The 1,3,5-triazines are among the oldest recognized organic compounds known and were 
discovered in 1776.[32] They have a symmetrical ring consisting of alternating carbon and 
nitrogen atoms joined by alternating single and double bonds. Compounds of this type are 
often referred to as s-triazines, the ring is numbered in the same manner as a benzene 
ring starting with a nitrogen atom as number one. 1,3,5-Triazine was unknowingly first 
synthesized by Nef in 1895 by treating hydrogen cyanide with ethanol in an ether solution 
saturated with hydrogen chloride. The resulting salt was then treated with base and 
distilled to give 1,3,5-triazine in a low yield of 10%. Nef incorrectly identified the product as 
a dimeric species, but Grundmann and Kreutzberger proved the compound to be a trimer 
of hydrogen cyanide, s-triazine in 1954.[33]
Triazine is thermally stable, and will decomposes to form hydrogen cyanide when heated 
to above 600 °C. The triazine ring is very resistant to electrophilic substitution. However, it 
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may easily undergo ring cleavage with nucleophiles and is fairly sensitive to hydrolysis by 
water and other hydroxyl-compounds to a lesser degree. A series of heterocyclic or related 
compounds can be synthesized from 1,3,5-triazine by introducing bifunctional amines or 
related compounds.
The most commonly used triazine derivatives are shown below in Figure 1-14, cyanuric 
acid 27, melamine 28 and cyanuric chloride 29.
 
Figure 1-14. Common triazine derivatives 27-29.
Triazines were first synthesized as the compound known as cyanuric acid 27. In 1776, 
Scheele pyrolysed uric acid and obtained cyanuric acid. In 1820, Serullas repeated the 
work of Scheele to produce cyanuric acid from cyanogen in water. In 1830, the two 
products were discovered to be the same, and the structure was elucidated by Liebig and 
Wohler.[34]
Cyanuric acid 27 is thermally unstable. It decomposes to from toxic cyanic acid at high 
temperature. Cyanuric acid exists preferentially as the oxo tautomer 27b rather than the 
hydroxy form 27a (Figure 1-15). Cyanuric acid is industrially prepared from the pyrolysis of 
urea(Scheme 1-2),[34] and it has many commercial applications such as stabilizers of 
swimming pool disinfectants, household bleach, industrial cleaners, dishwasher detergents 
and general sanitizers. Naturally occurring cyanuric acid has been found in soil humus.
 
                                                      27a                            27b
Figure 1-15. Tautomerism of cyanuric acid
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  
Scheme 1-2. Industrial synthesis of cyanuric acid. Condition: (a) 200-300 °C.
Melamine 28 was first prepared in 1834 by Liebig by fusing potassium thiocyanate with 
ammonium chloride and then work-up with base.[35] In recent days, melamine is industrially 
prepared from urea (Scheme 1-3).[34] Melamine has been found to naturally occur in 
nature in meteorites.[32] Melamine can be used to produce resins by reacting with 
formaldehyde (Scheme 1-4).[36]
Scheme 1-3. Industrial synthesis of melamine 28. Condition: (a) 390-410 °C.
Scheme 1-4. Resin preparation from melamine. Reagent: (a) 6 equivalents formaldehyde.
HN
N
H
NH
O
O O
a + 3 NH3H2N
O
NH2
3
27b
N
N
N
O
NH2H2N
NH2
H2N NH2
+ 6 NH3 + 3 CO26
a
28
N
N
N
NH2
H2N NH2
a N
N
N
N
N N
OHOH
OH
OHHO
HO
  / 13 156
Cyanuric chloride, trichlorotriazine 29, was first synthesized in 1827 by Serullas, who 
converted cyanogen chloride to cyanuric chloride using sunlight. The structure was 
thought to be the trimer of cyanogen chloride for many years, and then corrected by Liebig 
who prepared the compound by passing chlorine over dry potassium thiocyanate.[32] 
Cyanuric chloride is produced by the trimerization of chlorinated hydrocyanic acid 
nowadays (Scheme 1-5).[37]
 
Scheme 1-5. Serullas procedure (top) and industrial synthesis of cyanuric chloride 29 
(bottom)
Cyanuric chloride has the far more applications than any other triazine derivatives. The 
halogenated analogues can react easily with nucleophiles, and they are widely used in 
SNAr reactions to prepare derivatives of the triazine ring. The fundamental building block 
makes It more important than the cyanuric acid 27 when synthesizing the s-triazine series. 
It may be used as an analogous acid chloride equivalent in many organic transformations, 
including chlorination, dehydration, and coupling reactions.[38-41]
Cyanuric chloride has temperature-dependent differential reactivity for subsequent 
transformations of chlorides with nucleophiles during SNAr reactions. The incorporation of 
amino nucleophiles was selected as an example and the process is illustrated in Scheme 
1-6. 
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 Scheme 1-6. Different reactivity of cyanuric chloride. Reagents and conditions: (a) R1NH2, 
0 °C; (b) R2NH2, 25 °C; (c) R3NH2, 70 °C.
As a general rule, which varies from the reactivity of the nucleophile chosen, the first 
substitution occurs at low temperatures, 0 °C, the second substitution at around room 
temperature, and the third substitution at elevated temperatures, 70–100 °C[42-45]. This 
property allows substitution of three different nucleophiles onto the same triazine core, and 
numerous possible triazine derivatives can be provided.
1.6 Brief introduction to the biological and pharmaceutical applications of s-triazine 
scaffold based derivatives
s-Triazine is a versatile nuclei in various biologically active molecules. The triazine ring will 
imparts different activity after being substituted of various groups, which provides the basis 
of designing biologically relevant molecules with widespread applications in drug 
development.
Seo and co-workers[46] described a novel phenoxyl-triazine 30, which can reach the 
hydrophobic region of Hsp90 by van der Waals interaction with antiproliferative activity 
against gefitinib-resistant H1975 cells.
 
30
Figure 1-16. Hsp90 inhibitor 30
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Gahtori and co-workers[47] have synthesized a series of triazine substituted aromatic and 
heterocyclic amines as potential antibacterial agents. After structure-activity relationship 
studies, the presence of a nitro group such as in 31 was found to present the most 
effective antibacterial activity.
 
31
Figure 1-17. Phenylthiazoleetriazine hybrid 31.
Rawat and co-workers[48] described the quinoline moiety substituted with triazine 
functionalities that can decrease drug resistance while retaining antimalarial activity. 
Sunduru and co-workers synthesized a serious triazines bearing a quinoline moiety, and 
32 and 33 has been found to be the most active against a chloroquinoline sensitive strain.
[49] 
The synthesis of monosubstituted s-triazines were accomplished by nucleophilic 
substitution. Then they were subsequently reacted with N1-(7-Chloroquinolin-4-
yl)ethane-1,2-diamine. The targeted compounds were obtained after the third chloride 
atom was substituted with further nucleophilic amines.
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 Scheme 1-7. Quinoline substituted triazine derivatives 32 (above) and 33 (bottom). 
Reagents and conditions: (a) piperidine/morpholine, K2CO3, 0 °C to r.t., anhydrous THF, 
1h, 84% and 82%, respectively; (b) N1-(7-Chloroquinolin-4-yl)ethane-1,2-diamine, K2CO3, 
anhydrous THF, r.t., 4 h; (c) 3-Aminopropylmorpholine/N,N-Dimethylethylenediamine, 
K2CO3, 80 °C, 16 h, 71% and 74%, respectively.
HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTI) with high antiviral potency, 
specificity and low cytotoxicity have become an indispensable component in highly active 
antiretroviral therapy (HAART) regimen.[50] Liu and co-workers[51] have synthesized a novel 
series of diarylpyrimidines (DAPY) analogs bearing a piperidine triazine moiety. Among 
them, compounds 34 and 35 are the most potent derivatives which exhibited highest 
inhibitory activity against HIV-1. 
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The mono-substituted s-triazine was produced starting with cyanuric chloride and 2,4,6-
trimethylaniline at 0 °C in the presence of K2CO3. The second chloride was then replaced 
with another primary amine 4-amino-1-Boc-piperidine. Then the third chlorine atom of the 
product was transformed to methylamino/oxyl group under the conditions of NH2CH3 (aq)/
NaHCO3/THF or Na/CH3OH, respectively. The protecting group was then removed in the 
presence of trifluoroacetic acid (TFA) at room temperature. The benzyl substituent was 
then introduced to the substituted the secondary amide.
 
Scheme 1-8. DAPY derivatives. Reagents and conditions: (a) K2CO3, dimethylaniline, 
THF, 0 °C, 3 h, 91%; (b) NaHCO3 (5% aq), 4-amino-1-Boc-piperidine, THF, 30 °C, 8 h, 
92%; (c) NaHCO3 or Na/CH3OH; (d) TFA, CH2Cl2; (e) 4-cyanobenzyl chloride, K2CO3, 
anhydrous DMF, r.t., overnight, 68% and 61%.
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Variously substituted s-triazine drugs are widely used in the clinic, and some of them are 
listed in Table 1-1.
Table 1-1. Commercial drugs containing triazine nucleus
Drug name Structure Uses
Altretamine Refractory ovarian cancer
Triethylenemelamine Antineophlastic
Melamine African trypanosomiasis
Atrazine Itching caused by allergies
HMPMM Anti-tumor 
Dioxadet Anti-tumor
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In this thesis, we aim to develop some triazine-based anti-cancer agents. To start with 
commercial available cyanuric fluoride/chloride, moieties such as benzyl (e.g. 2,4-
dimethoxyphenyl) or amine (e.g. piperazine) will be attached and some mono-, di- or tri-
substituted triazines may be formed based on the procedures mentioned above. 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Section 3: Introduction to the background of Epidermal Growth 
Factor Receptor (EGFR) and EGFR inhibitors
1.7 Introduction of Non-Small Cell Lung Cancer (NSCLC)
Between 85% to 90% of lung cancers are identified as non-small cell lung cancer 
(NSCLC). There are three main subtypes of NSCLC (squamous cell carcinoma, 
adenocarcinoma and large cell carcinoma). The cells in these subtypes differ in size, 
shape, and chemical make-up when looked at under a microscope, but they are grouped 
together because the approach to treatment and prognosis are often very similar. NSCLC 
is a very aggressive form of neoplasm, more responsible for cancer deaths each year than 
colon, breast, pancreas and prostate cancers combined together.[52]
1.8 Introduction to EGFR and EGFR inhibitors
Cancer cells are progressive with a gradual transition from normal cells to benign tumors 
to malignant tumors. They have abnormal membranes and cytoskeletal proteins, and grow 
and divide at an uncontrolled rapid rate. Over the last 20 years, research efforts has aimed 
to clarify, and to specifically interfere with the essential alterations in cell physiology that 
characterize malignancy. Recent research efforts have been focused on developing tumor-
specific therapies associated with chemotherapy, which will give theoretically minimum 
debilitating nonspecific toxicities. By focusing on key molecules integral for cellular 
function, replication, or tumorigenesis, such specific therapies may exert cytostatic or 
cytotoxic effects on tumor cells.
The epidermal growth factor receptor (EGFR) is a transmembrane glycoprotein that 
constitutes one of four members of the erbB family of tyrosine kinase receptors. Binding of 
EGFR to its natural ligands leads to autophosphorylation of receptor tyrosine kinase and 
subsequent activation of signal transduction pathways that are involved in regulating 
cellular division, differentiation, and survival. Although present in normal cells, EGFR is 
overexpressed in a number of tumor cell lines and has been associated with poor 
prognosis and decreased survival. EGFR activation also plays a role in resistance to 
chemotherapy and radiation treatment in tumor cells.
Over the last two decades, a lot of work has been directed at developing anticancer agents 
that can block with EGFR activity. The most common pharmacologic approaches to 
inhibiting EGFR have been developed are monoclonal antibodies and low molecular 
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weight inhibitors. Monoclonal antibodies block ligand binding to the extracellular domain, 
whereas the small-molecule inhibitors exert their effects on the intracellular part of the 
receptor to stop tyrosine kinase phosphorylation and further activation of signal 
transduction pathways. A number of EGFR inhibitors have been developed that can arrest 
tumor growth and, in some cases, cause tumor regression. When used together with 
cytotoxic treatments, chemotherapy, or radiation therapy, EGFR inhibitors have been able 
to enhance their anticancer activity.[53]
In NSCLC, studies have shown that the EGFR is overexpressed in up to 80% of cases, 
depending on histology.[54] Data from many studies indicate that, on average, 84% of 
tumors with squamous cell histology will be positive for EGFR.[55] The mean percentages 
of large cell and adenocarcinomas reported to be positive for EGFR are 68% and 65%, 
respectively. Overexpression of EGFR in NSCLC is correlated with a high metastatic rate, 
poor tumor differentiation, and a high rate of tumor growth.[56] Median survival also 
decreases as the degree of EGFR expression increases, although this conclusion is not 
supported by all studies.[57,58]
Several approaches have been developed to target the EGFR to interfere with EGFR-
mediated cellular effects. The two most intensively studies so far consist of monoclonal 
antibodies acting directly against the extracellular receptor domain and small-molecule 
drug compounds that interfere with EGFR tyrosine kinase activity inside the cell. The 
differing mechanism of action and toxicity profiles of these agents compared with those of 
traditional cytotoxic compounds, radiation and chemotherapy, provide an ideal rationale for 
evaluating them in combination with cytotoxic approaches to attempt to achieve additive or 
even synergistic anticancer activity.
Two orally active low-molecular-weight tyrosine kinase inhibitors (TKIs), ZD1839 (Gefitinib, 
Iressa) and OSI-774 (Erlotinib, Tarceva) (Figure 1-18), have produced specific, reversible 
inhibition of EGFR tyrosine kinase.[59,60] Gefitinib and erlotinib have induced clinical 
responses in NSCLC with activating mutations within the EGFR kinase domain.[61-63] 
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   
Gefitinib                                             Erlotinib    
Figure 1-18. Chemical structures of Getinib and Erlotinib, both of them contain a central 
quinazoline, with aniline and solubilising groups.
Clinically, the efficacy of these TKIs is often of limited duration because of the emergence 
of drug resistance conferred by a second mutation: substitution of threonine 790 with 
methionine (T790M). Threonine 790 is the residue in EGFR located at the entrance to a 
hydrophobic pocket in the back of the ATP binding cleft, which makes it an important 
determinant of inhibitor specificity in protein kinases. Yun and co-workers indicated that the 
introduction of the T790M mutation increased the ATP affinity of the oncogenic activating 
mutant. The increased ATP affinity is the primary mechanism by which the T790M 
mutation confers drug resistance.[64-66] The T790M mutation accounts for about half of all 
resistance to gefitinib and erlotinib.[67] To overcome the T790M mutation related resistance, 
irreversible ATP-competitive EGFR inhibitors bearing a Michael addition receptor moiety 
have been developed. For example, Wissner and co-workers prepared 6-amino-4-
anilinoquinoline-3-carbonitriles 36 as shown in Scheme 1-9.[68] However, these irreversible 
inhibitors present limited clinical efficacy which is caused by their high toxicities and 
decreased binding velocity to the mutant kinase.
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 Scheme 1-9. Synthesis of 6-Nitro–4-anilinoquinoline-3-carbonitrile building block 36 by 
Wissner et al. Reagents and conditions: (a) Toluene, reflux; (b) Dowtherm, 258 °C.
In recent days, it has been highly desirable to develop novel reversible EGFR inhibitors 
which can inhibit the drug resistant T790M bearing mutants and remain potent in other 
activating mutants.[69-72]
Yang and co-workers indicated that a 2,8-dianilinopurine analogue, N2-(4-(4-
methylpiperazin -1-yl)phenyl)-N8-phenyl-9H-purine-2,8-diamine 37 (Figure 1-19), exhibited 
an ability to inhibit both EGFR-activating and resistance mutations.[20] However, the 
potency against the T790M EGFR mutation of this compound was relatively poor, which 
made it incapable of overcoming the enhanced ATP binding found in T790M EGFR. 
 
37
Figure 1-19. Structure of inhibitor 37
Yang and co-workers then successfully optimized 38 from 37 in good yields. The aniline 
groups at C-2 and C-8 were retained and a cyclopentyl group was attached at N-9 of the 
purine scaffold. This allowed compound 38 to exhibit significant in vitro antitumor potency 
against the NSCLC cell lines HCC827 and H1975, which harbor EGFR-activating and drug 
resistance mutations, respectively. In further tests, compound 38 was indicated as a highly 
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potent kinase inhibitor against both EGFR-activating and resistance mutations in vivo anti-
NSCLC studies.
 
38
Figure 1-20. Structure of optimized purine inhibitor 38
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The synthetic route to the 2,8-dianilinopurine derivative 38 is shown in Scheme 1-10.
 
Scheme 1-10. Reagents and conditions: (a) 1-methylpiperazine, K2CO3, DMSO, r.t., 6 h, 
95%; (b) H2, 10% Pd/C, EtOH, r.t., 9 h, 90%; (c) CH2Cl2, DIEA, cyclopentylamine, -60 °C 
to room temperature, 60-75%; (d) n-butanol, 90 °C, 5 h, 76%; (e) H2, 10% Pd/C, MeOH, 
50 °C, 6 h, 85%; (f) CH2Cl2, DIEA, EDIC, isothiocyanatobenzene, reflux, 12 h, 35−60%.
The preparation of the first main aniline intermediate 40 began with commercially available 
4-fluoronitrobenzene which was reacted with 1-methylpiperazine in the presence of K2CO3 
in DMSO to produce the intermediate 39. Catalytic hydrogenation of the nitro group in 39 
with palladium on carbon (Pd/C) provided the desired aniline 40 in excellent yield. The 
second main intermediate 41 is synthesized with commercially available 2,4-dichloro-5-
nitropyrimidine with cyclopentylamine. Nucleophilic aromatic substitution of the 2-chloro-
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position in 41 with 40 in n-butanol at 90 °C yielded compound 42. Subsequent 
hydrogenation of the nitro group in 42 using Pd/C as a catalyst provided a good yield of 
the desired intermediate 43, which was treated with isothiocyanotobenzene to produce the 
final 2,8-dianilinopurine derivative 38.
Continued research into new methods for heterocyclic synthesis thus remains important 
for medicinal chemistry and the development of new drugs to combat cancer and other life 
threatening diseases. In this thesis, we therefore aim to synthesis a new target scaffold 
around the kinase inhibitor 38. The aniline and piperazine groups would be remained in 
our structure, and the preparation would based on the procedure mentioned above.
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Section 4: Fluorinated aromatic compounds 
1.9 Orientation of substitution reactions in polyfluorinated compounds
As a key part of the strategy proposed for the new targets in this work involves stepwise 
SNAr reactions of per-fluorinated arenes such as pentafluoropyridine, the chemistry of 
these highly fluorinated arenes is now discussed.
Similar to electrophilic substitution in benzene derivatives C6H5X, the nucleophilic reaction 
of perfluorobenzene derivatives, C6F5X, with nucleophiles can give three sites of attack, 
ortho, meta and para relative to the group X. 19F NMR spectroscopy has be used used 
since the very early work to assist in the structure determination of such compounds[73].
The variation in the proportions of ortho, meta and para substitution of fluorine by 
nucleophiles in C6F5X compounds is very uneven and can be profoundly influenced by the 
nature of the solvent (X could either be electron donating or withdrawing) (Scheme 1-11).
[74] Meta substitution is the least common site of attack and requires vigorous conditions. 
The major substitution product from the vast number of C6F5X compounds which have 
been reacted with nucleophiles is the para isomer. 
 
                                            Meisenheimer intermediate
Scheme 1-11. Para substitution in C6F5X compounds via Meisenheimer intermediate
Nucleophilic substitution of fluorine in pentafluoropyridine, the first heterocyclic compound 
to be prepared,[75] occurs initially almost exclusively at the 4-position, due to stabilization of 
the charge on the tetrahedral intermediate by nitrogen.[76]
 
Scheme 1-12. Nucleophilic substitution of hexafluorobenzene and pentafluoropyridine. 
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Conditions: (a)Nucleophile 1; (b)Nucleophile 2.
Orientation effects also occur in polyfluorinated systems containing five-membered rings 
with six π electrons. For example, tetrafluorothiophene undergoes substitution at the 2-
position under the conditions of NaOMe/MeOH at room temperature (Scheme 1-13).[77]
 
Scheme 1-13. Substitution of the 2-fluorine. Reagents and conditions: NaOCH3/MeOH, 60 
˚C.
1.10 Brief introduction to 19F NMR spectroscopy
As 19F NMR spectroscopy is less widely known and used than 1H or 13 C NMR, it is 
introduced briefly here.
As the new target compounds and the synthetic intermediates leading to them, contain 
fluorine which is an NMR active nucleus, the background to 19F NMR spectroscopy is 
reviewed here as this is a powerful analytical method that was used to assist in structure 
determination in the research reported in this thesis.
Current synthetic methods make possible the production of fluorine-containing analogs of 
amino acids, nucleosides, lipids and sugars, as well as a wide variety of molecules that are 
important drugs and agricultural chemicals. Fluorine 19, at 100% natural abundance, is a 
spin 1/2 nucleus. The technology for obtaining fluorine NMR spectra is virtually the same 
as that involved in acquiring proton NMR data. However, because a fluorine nucleus in a 
molecule is on average surrounded by nine electrons, rather than a single electron as is 
the case with hydrogen, the range of fluorine chemical shifts and the sensitivity of fluorine 
chemical shifts to the details of the local environment are much higher for fluorine than 
hydrogen. Signals are thus usually well spaced and give valuable structural information 
about the compounds under investigation.
The reference signals used for proton and carbon-13 NMR spectroscopy are those from 
tetramethylsilane (TMS). Fluorine chemical shifts span a very wide range and there is no 
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single fluorine-containing compound that is experimentally convenient for use as a 
universal reference compound.[78]
A fluorine reference is usually a compound that is chemically similar to the one under 
examination. The typical chemical shift values are shown in Table 1-2. 
Table 1-2. Typical 19F NMR chemical shifts. Negative (-) values correspond to upfield 
shifts, higher-shielding, or lower frequency.
Fluorine will also exhibit strong coupling to protons or carbon atoms in a molecule which 
can give useful information about structure and orientation of substituents. A  disadvantage 
Compound Formular Structure
Chemical shifts 
versus CFCl3 /
(p.p.m.)
Trichloro-fluoromethane CFCl3 0.00
Hexafluorobenzene C6F6 -164.90
Monofluorobenzene C6H5F -113.15
Trifluoro-toluene C7H5F3 -63.72
Pentafluoropyridine[70] C5F5N
-88.5
-132.5
-160.5
Trifluoro-triazine[71] C3F3N3 -31.3
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however is the reduced intensity of C-F signals, particularly weak aromatic signals, thus 
requiring long acquisition times to detect all signals.
19F NMR spectroscopic results will be discussed throughout the thesis, as it proved to be 
an essential analytical tool in structure determination. 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Chapter 2: Results and 
Discussion
Section 1: 
One of our aims was to synthesise the revised structure of acremolin 23 and compare its 
spectroscopic data with that of the natural product isolated by Shin[26] to confirm if the 
proposed revised structure was correct. The revised structure of acremolin was first 
planned to be synthesized in five steps from guanosine, and the proposed synthetic route 
is shown below (Scheme 2-1). 
 
Scheme 2-1. Proposed synthesis of the revised structure of acremolin 23 from guanosine.
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Guanosine 8 was selected as the starting material as the imidazole nitrogen is already 
blocked with the ribose ring, which allows methylation to occur on the pyrimidine ring 
directly. The second fused imidazole 44 will be formed by reacting 8 with chloroacetyl 
chloride after the solubility modification on the ribose ring. In the last two steps, 45 will be 
treated with trifluoromethanesulfonic anhydride to provide triflate derivative 46 before the 
introduction of the isopropyl group by palladium catalysed coupling to give the target 
product 23.
2.1 Solubility modification of guanosine
As guanosine 8 is largely insoluble in general organic solvents, three reagents, acetic 
anhydride, propionic anhydride and octanoyl chloride were employed to modify the 
hydroxyl groups on the ribose ring (Scheme 2-2) yielding the products 48-50. The 
reactions were run with the following conditions (Table 2-1).
 
Scheme 2-2. Solubility modification of guanosine. Reagents and conditions: (a) pyridine, 
DMF, 100 ˚C, 2 h.
Table 2-1. Compounds obtained
In the case of esterification with acetic anhydride the currently accepted mechanism 
involves three steps. First, pyridine and acetic anhydride form in an equilibrium reaction a 
labile ion pair between the acetate and the acetyl-pyridinium ion. In the second step the 
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Entry Reactant Product R Yield
1 Acetic anhydride 48 Acetyl 75
2 Propionic anhydride 49 Propionyl 70
3 Octanoyl chloride 50 Octanoyl —
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alcohol attacks the acetyl group to form the ester. In this step the acetate counterion 
removes the proton from the alcohol while the alcohol forms a covalent bond with the 
acetyl group. The bond from the acetyl group to the catalyst is cleaved to generate the 
catalyst and the ester. The acetic acid formed will then protonate the pyridine. In the last 
step of the catalytic cycle the auxiliary base deprotonates the protonated pyridine, 
reforming the catalyst[81] (Scheme 2-3).
 
Scheme 2-3. 
It has been reported that using pyridine and DMF as a mixed solvent could increase the 
yield of the product. The quaternary ammonium salt formed by pyridine and acetic 
anhydride could play a significant role as an acylating agent. The large polarity of DMF 
generates good solubility of the starting materials. The yield reached the peak when the 
amount of acetic anhydride increased till nguanosine: acetic anhydride reached 1: 10, and then 
changed very slightly.[82]
In entry 1 and 2, reactions proceeded smoothly without any difficulties in good yields (75% 
and 70, respectively). The pure products were obtained as white fine powders after 
purification via column chromatography.
In 1H NMR spectroscopy, signals representing the acetyl/propionyl showed the right ratio 
to that of the hydrogen atoms and the diastereotopic protons attached to the ribose ring. 
As a result, compound 48 could dissolved in organic solvents like dichloromethane, while 
compound 49 could only  be dissolved in some more polar organic solvents like pyridine.
In entry 3, the starting material spot presented after four hours stirring by tracking by the 
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TLC, and the reaction mixture stayed very turbid, and could not be filtered or dissolved in 
neither water nor ethyl acetate. The reason was not clear, and the reaction was 
discontinued.
Figure 2-1. 1H NMR spectrum of 2’,3’,5’-tripropanoate-guanosine 49, the ribose hydrogen 
(red grid) and the propionyl hydrogen (green grid) in DMSO-d6. 
2.2 synthesis of 2’,3’,5’-tripropanoate-N-(2-chloroacetyl)-guanosine 51
In the next step we aimed to form 51 which involved treatment of 48 and 49 with 
chloroacetyl chloride (Scheme 2-5).
Compound 48 and chloroacetyl chloride were stirred in pyridine at 0 ˚C. The reaction 
mixture formed a brown gel after a very short period. This could be due to the by-product 
formed by reaction of the chloroacetyl chloride and pyridine. As a result, the reactant 
needed to have better nucleophilic solubility in a less polar solvent.
The second approach was started with 2’,3’,5’-tripropanoate-guanosine 49, chloroacetyl 
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chloride and N-ethyldiisopropylamine formed 2’,3’,5’-tripropanoate-N-(2-chloroacetyl)-
guanosine 51 in good yield. 
 
R = propionyl
Scheme 2-5. Synthesis of 2’,3’,5’-tripropanoate-N-(2-chloroacetyl)-guanosine 51. 
Reagents and conditions: (a) chloroacetyl chloride, N-ethyldiisopropylamine, anhydrous 
THF, 65 ˚C, 2 h, 73%.
The reaction was firstly run with triethylamine, 80% of the starting material was recovered 
even though the chloroacetyl chloride was added in excess and the reaction time was 
increased to18 hours. The could be due to the high reactively of chloroacetyl chloride may 
have reacted with triethylamine. The reaction finished in 2 hours after a more hindered 
base N-ethyldiisopropylamine was used in excess.
In the high resolution mass spectrum, the signal representing C21H2735ClN5O9+ was 
observed, which indicated that the chloroacetamide 51a had formed but did not 
spontaneously ring close to the tricyclic imidazo-purine 51b. This was also proved by the 
presence of two broad singlet signals at δ= 11.92 and 10.38 which represented on NH 
groups. In addition, a new singlet representing the new introduced CH2 group (δ=4.36 
p.p.m.) in 1H NMR spectrum. The delocalized electrons between three nitrogen atoms give 
rise to a tautomer/rotamer mixture of 51c, 51d and 51e, which may also inhibit the 
cyclization activation.
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 Scheme 2-6. Cyclization of 51a.
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2.3 Synthesis of 2’,3’,5’-tripropanoate-N-(2-chloroacetyl)-1-methyl-guanosine 52
The next step was to methylate the N-1 of the purine ring in 51 with iodomethane to give 
2’,3’,5’-tripropanoyl-N-(2-chloroacetyl)-1-methyl-guanosine 52 in fair yield (Scheme 2-7).
 
Scheme 2-7. Synthesis of 2’,3’,5’-tripropanoate-N-(2-chloroacetyl)-1-methyl-guanosine 52. 
Reagents and conditions: (a) iodomethane, anhydrous THF, 40 ˚C, 8 h, 46%.
This proceeded smoothly without any difficulties and resulted in fair yields. This pure 
product was obtained as yellow solid after the purification via column chromatography. In 
1H NMR spectroscopy, a new signal at δ=3.28 p.p.m. represents the N1-CH3. This was 
also proved by 13C spectroscopy (a new signal at δ=32.98) and HRMS spectroscopy 
([M+H]+ signal matching the expected composition).
Conclusion
Guanosine was successfully modified with acetic anhydride and propionic anhydride, and 
2’,3’,5’-tripropanoate-guanosine 49 was then used as the starting material in the next step 
due to its good solubility. Chloroacetyl chloride was successfully attached to NH2 group on 
C-2. However, the compound 51 failed to spontaneously ring close. The methylation 
reaction proceeded smoothly at N-1 position, and a precursor to the revised structure of 
acremolin was successfully formed. 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2.4 First total synthesis of acremolin
After we had started our investigation, the first synthesis of the revised structure of the 
heterocyclic marine natural product, acremolin, was reported (Scheme 2-8).[83]
 
Scheme 2-8. Lawrence procedure.
Lawrence and co-workers chose to prepare 1-methylguanine 53 by methylation of 
guanosine, and followed by hydrolysis of the nucleoside. Protection of 53 gave a mixture 
of N7- and N9-PMB derivatives 54, 55 (∼1.6:1, 56%) from which 54 could be isolated by 
fractional crystallization (EtOH). Reaction of 54 with bromoketone 56 returned the N2,3-
ethenoguanine derivative 57 (27%) as a single isomer, along with the guaninium salt 58 
(54%) resulting from monoalkylation of the imidazole ring. The PMB group was removed 
under the conditions reported by Fujii and co-workers (90% aq H2SO4, toluene, 40 ˚C),[84] 
and smoothly delivered samples of 23 of high purity, albeit in low yield (39%).
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2.5 Synthesis of the revised structure of acremolin from imidazole
Despite this, we wanted to finish our synthesis (and adapt it to form analogues which might 
have useful biological activity). 
A alternative synthetic plan had also been considered, which involved coupling two 
imidazole precursors to build up the imidazopurine core. As this route differed from 
Lawrence’s method we decided to investigate this approach which is outlined in Scheme 
2-9.
 
Scheme 2-9.
The second part of the research began by firstly aiming towards the formation of two 
fragments: 4-isopropyl-2-methylthio-1H-imidazole 62 and 4-iodo-1-[(4-methoxyphenyl)
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methyl]-1H-imidazole-5-carboxylic acid 61. Compound 62 was proposed to be synthesized 
via a cyclization reaction between a bromoketone 56 and a thiouronium salt 63, while 
compound 61 was proposed to arise after sequential substitution reactions starting with 
imidazole. Two precursors would be coupled together, and the cyclization reaction in next 
step would employ methyl amine as the reagent to close the purine ring.
2.6 Synthesis of 2-methylthio-4-isopropyl-1H-imidazole 62
We obtained 4-isopropyl-2-methylthio-1H-imidazole 62 successfully by a 2-step reaction 
Scheme 2-10.
 
Scheme 2-10. Synthesis of 2-methylthio-4-isopropyl-1H-imidazole 62. Reagents and 
conditions: (a) bromine, methanol, 0 ˚C, 2 h, 95%; (b) S-methylisothiourea hemisulfate 
salt, sodium hydride, DMF, room temperature, 8 h, 16%.
Dickschat and co-workers had synthesized 2-bromo-3-methyl-2-butanone 56 at low 
temperature, -78 ˚C yielding the product in 79% (Scheme 2-11)[85].
 
Scheme 2-11. Dickschat procedure. Reagents and conditions: (a) bromine, pentane, -78 
˚C, 79%.
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We produced the compound 56 with a different solvent at a higher temperature and 
obtained the same product in excellent yield (95%).
 
Scheme 2-12. Synthesis of 56. Reagents and conditions: (a) bromine, methanol, 0 ˚C, 2 h, 
95%.
This proceeded smoothly without any difficulties and resulted in excellent yields. GC-MS 
confirmed the expected composition, C5H9BrO by the presence of signals at 163.9 and 
165.9 m/z representing the two isotopes of bromine. In addition, the product caused eye 
irritation characteristic of α-halo-carbonyl compounds. This stage was repeated on a 20 
mmol scale. In addition, this stage was also tried on a 40 mmol scale. However, the yield 
of the predicated mono-substituted product was lowered, as the di- or tri-brominated by-
products were formed in a capricious reaction. 
The second step was to condense the bromoketone 56 with a thiouronium salt 63 to form 
the desired imidazole 62 (Scheme 2-13). This worked but led to the product in a very 
disappointing 16% yield. The reactions were run with the following conditions (Table 2-2).
 
Scheme 2-13. Synthesis of 62. Reagents and conditions: NaH, DMF, room temperature, 8 
h, 16%.
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Table 2-2.
As the S-methylisothiouea hemisufate salt could only be dissolved in water, ethanol and 
water were used as a mixed solvent in entry 1 and 2. In addition, sodium ethoxide was 
selected as both the base in ethanol as solvent in entry 3. Unfortunately, all three reactions 
formed complex product mixture and none of the fractions obtained after chromatography 
proved to be the expected product after analysis by 1H NMR and MS spectroscopy.
At last, the desired product was isolated after column chromatography in entry 4.
Conclusion
The synthesis of the first imidazole precursor, 4-isopropyl-2-methylthio-1H-imidazole 62, 
proceeded smoothly via two steps reactions, and then the bromoketone 56 was prepared 
in excellent yield. After trials with different conditions of bases, solvents and temperature, 
the desired product was formed successfully iwith the use of sodium hydride in DMF.
Entry Solvent Base Reaction temperature
Reaction 
time/(hours)
Yield/
(%)
1 Ethanol and water Triethylamine Reflux 4 —
2 Ethanol and water
Sodium 
hydroxide Reflux 4 —
3 Sodium ethoxide (neat) Reflux 8 —
4 DMF Sodium hydride room temperature 8 16
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2.7 Synthesis of 4-iodo-5-carboxylic-1-[(4-methoxyphenyl)methyl]-1H-imidazole 61
The desired compound 61 was obtained after three consecutive substitution reactions 
(Scheme 2-14).
 
Scheme 2-14. Synthesis of 61. 
The first stage was to introduce iodine into positions 4 and 5 replace the 4,5-hydrogens at 
imidazole 67 by iodine and gave 66 (Scheme 2-15) in 75% yield.[77]
 
Scheme 2-15. Synthesis of 4,5-diiodo-1H-imidazole 66.[86] Reagents and conditions: 
Iodine, NaOH, hexane, deionized water, room temperature, 8 h, 75%. 
This proceeded smoothly without any difficulties and resulted in good yields.  The reaction 
mixture was stirred in a basic environment to allow deprotonation of imidazole. The 
reaction was quenched with 1M HCl until the pH reached 7, the crude product was 
precipitated. After recrystallization with dilute ethanol, the product 66 was formed as a fine 
white powder. The melting point (175 ˚C) confirmed this by comparison with the literature 
value (180 ˚C)[86].
The second stage involved alkylation to form the 4,5-diiodo-1-(4-methoxybenzyl)-1H-
imidazole and gave 64 in 91% yield.
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 Scheme 2-16. Synthesis of PMB-protected imidazole 61. Reagents and conditions: PMB-
Cl, sodium hydride, anhydrous THF, 55 ˚C, 12 h, 91%.
This proceeded smoothly without any difficulties and resulted in excellent yields. The 
reaction mixture was stirred at 0 ˚C for 1 hour to allow the deprotonation of 4,5-diiodo-
imidazole 66. This pure product gave the same melting point (157 ˚C) compared with the 
literature[78].
Knochel and co-workers reported a iodine-copper exchange reaction (Scheme 2-17). The 
introduced (Nphyl)2CuLi2 presented precomplexation to the protecting group (CH2OEt or 
Ts) favoring the iodine copper exchange in the ortho-position. Various electrophiles (e.g. 
EtCOCl) provided the corresponding products in good yields.[87]
 
Scheme 2-17. Knochel’s iodine-copper exchange reaction.
For replacing the iodo-group with the desired ester moiety, the stronger base BuLi was 
employed to effect lithium halogen exchange (Scheme 2-18).
 
Scheme 2-18. Synthesis of 64. Reagents and conditions: (a) nitrogen protection i) n-BuLi, 
anhydrous THF, ii) ethyl chloroformate, r.t., 8 h, 60%.
The desired product 64 was produced smoothly without any difficulties and resulted in fair 
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yields. This pure product was obtained as yellow oil after the purification via column 
chromatography. In 1H NMR spectroscopy, new signals at δ=4.36 and 1.32 p.p.m. 
represent the newly introduced ethyl group. This was also proved by HRMS spectroscopy 
([M+H]+ signal matching the desired product).
Conclusion
The second precursor, ethyl 4-iodo-1-[(4-methoxyphenyl)methyl]-1H-imidazole-5-
carboxylate 61, was synthesised successfully via a three step reaction. The 4,5-position 
hydrogens were firstly substituted by iodine. And then the amine group was protected with 
PMB group to give the desired product 64 in excellent yield. One of the iodine atoms was 
replaced by the carboxylate group using lithium halogen exchange, and which was 
identified by 1H, 13C NMR spectroscopy and its high resolution mass spectrum.
Although compound 61 was successfully prepared, due to lack of time, and the low yield of 
the other imidazole component 62 we were not able to investigate the coupling of the two 
imidazole fragments to compete the core of the acromelin molecule, and further work 
would be required to complete the natural product target by this approach. 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2.8 Other attempts to prepare guanosine and imidazole derivatives
Despite the bioactivity of acremolin being still not totally investigated, we still wanted to 
synthesis some of derivatives of it. Thus, a number of precursors were prepared based on 
our products formed above.
We synthesized two analogues 7-(propan-2-yl)-1-(2,3,5-tri-O-propanoylpentofuranosyl)-1H 
-imidazo[2,1-b]purin-4(5H)-one 68 and 7-phenyl-1-(2,3,5-tri-O-propanoylpentofuranosyl)- 
1H-imidazo[2,1-b]purin-4(5H)-one 69 based on Lawrence’s last procedure. 
 
                                                                                             68 R=propan-2-yl
                                                                                             69 R=phenyl
Scheme 2-19. Synthesis of analogues 68 and 69. Reagents and conditions: (a) 1-
bromo-3-methyl-2-butanone in 68 or 2-bromo-1-phenylethanone in 69, sodium hydride, 
DMF, 80 ˚C, 12 h, 20% and 12%, respectively.
Both analogues 68 and 69 were isolated in poor yields after the purification via column 
chromatography. In 1H NMR spectroscopy of compound 68, most signals belonging to the 
compound 49 remained the same, the broad singlet represented the NH2 at C-2 
disappeared. In addition, a new singlet signal at δ=7.38 p.p.m., which belongs to the new 
ring formed, reached the agreement with that reported in the literature.[83] 
However, the 13C NMR spectroscopy for both compounds 68 and 69 were very poor, as 
most signals were very weak due to the aromatic carbon skeleton. We also confirmed the 
products in the HRMS by the matching theoretical [M+H]+ signal at 512.5022 and 
552.5664, respectively.
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The imidazole analogues, 70 (Scheme 2-20), 71 and 72 were prepared following the same 
procedure of the synthesis of imidazole 62. It was to condense the bromoketones with 
acetamidine groups to formed imidazoles (Table 2-3).
 
Scheme 2-20. Synthesis of 70. Reagents and conditions: sodium hydride, DMF, r.t., 8 h, 
35%.
Sodium hydride was chosen as the base and DMF was used as the very polar solvent. 
The solution was stirred at room temperature for overnight. The complex product was 
purified by a column chromatography and the desired products were collected.
Table 2-3.
Similar to compound 62, 4-isopropyl-2-methyl-1H-imidazole 70 was isolated as a pale 
yellow oil. The other two 4-phenyl-substitued imidazoles 71 and 72 were formed as yellow 
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Compound Structure Starting material Reagent Yield/(%)
70 1-bromo-3-methyl-2ketone acetamidine 35
71 2-bromo-1-phenyl-ethanone acetamidine 28
72 1-bromo-3-methyl-2ketone
S-
methylisothioure
a hemisulfate 
salt 
18
 
N NH
 
N NH
S
 
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solids, and the melting points (158 ˚C and 134 ˚C, respectively) were close to those 
reported before (159 ˚C and 137 ˚C, respectively).[89,90] In 1H spectra of both compounds, 
signals were presented in correct ratios at the expected chemical shifts. 
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Section 2:
2.9 Synthesis of 2,4-difluoro-6-monosubstituted s-triazines
A new highly-fluorinated class of compounds class was firstly described by Chambers in 
1992[91] including the 2,4,6-trifluorotriazine. Aromatic amines were found to act as carbon 
nucleophiles in reactions with the highly electron deficient fluorinated triazine as shown in 
Scheme 2-21.
 
                         73                                                                            74
Scheme 2-21. Chambers procedure[91]
As part of our research to develop new triazine derivatives we repeated the reaction of 73 
with N,N-dimethylaniline. We obtained 74 (Scheme 2-22) successfully in a yield of 33% 
(Chamber’s yield 28%).
The first fluoride was to be substituted with an electron-donating dimethylaminophenyl 
moiety as this was known to react with the need for activation. The following substitution 
reaction should then proceed smoothly, and the conditions would be more easily 
controlled.
 
                                             73                                       74
Scheme 2-22. Addition of N,N-dimethylaniline to cyanuric fluoride 73. Reagent and 
conditions: (a) N,N-dimethylaniline, acetonitrile, reflux, overnight.
Addition of N,N-dimethylaniline to a solution of cyanuric fluoride in acetonitrile gave an 
immediate blue coloration, but on heating under reflux the color changed to dark red. The 
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blue color was presumably due to a charge-transfer interaction. 
The amount of cyanuric fluoride was added slightly in excess as it could easily be removed 
as the product was formed as a solid. After overnight reaction, the unwanted by-products 
including 2-fluoro-4,6-di-(N,N-dimethylamino-benzen-4-yl)-s-triazine and 2,4,6-tri-(N,N-
dimethylamino-benzen-4-yl)-s-triazine were not isolated formed. The melting point of 74 
(235 ˚C) was very close to the compound in literature (234 ˚C). A single peak was shown in 
19F NMR spectrum also demonstrated that the two fluoric groups were mirror imaged. The 
yield was a slightly higher than that shown in literature (28 %).[91]
2.10 Synthesis of 2-fluoro-4,6-disubstituted s-triazines
Compounds consisting of di-aryl substituted s-triazines were of interest as potential anti-
cancer drugs (unpublished results from our collaborators), and the synthesized 
heterocycles are undergoing testing for biological activity with collaborators at De Montfort 
University.
Two Grignard reagents (2,4-dimethoxyphenyl)-magnesium bromide 75 and (1,3-
benzodioxole)-magnesium bromide 76 were prepared in dried flasks as THF solutions 
(Figure 2-2) as these oxygenated arenes had shown good activity in related compounds 
prepared by collaborators. 
                 
75                                      76
Figure 2-2. Grignard reagents 75 and 76
The aromatic bromide was dissolved in anhydrous THF and added dropwise to 
magnesium powder under a nitrogen atmosphere. After the mixture was heated under 
reflux for 2 hours, the magnesium powder was consumed. The system was allowed to cool 
to room temperature. The grey colored slurry are then used directly in the required 
experiments with the fluorinated triazine 74. 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We successfully obtained a 2,4-diaryl substituted s-triazine compound, 2-fluoro-4-(N,N-
dimethylaminophenyl)-6-(2,4-dimethoxyphenyl)-s-triazine 77 starting with the 74 either 
using Grignard reagent (Scheme 2-23) or lithiated arene (Scheme 2-24, Table 2-4). The 
lithium could have a stronger electron-withdrawing inductive effect than magnesium, thus 
both reactions should proceed smoothly.
 
77 Ar: 2,4-dimethoxyphenyl
78 Ar: 1,3-benzodioxole-5-yl
Scheme 2-23. Substitution reaction with Grignard reagent. Reagents and conditions: ArBr, 
Grignard reagent, anhydrous THF, 0˚C to r.t., overnight
 
Scheme 2-24. Substitution reaction with organolithium reagent. Reagents and conditions: 
ArBr, n-BuLi, anhydrous THF, -78˚C to r.t., overnight.
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Table 2-4. The 2,4-diaryl substituted s-triazine 77 and 78.
One of the remaining fluorine atoms in 74 was then replaced by 2,4-dimethoxyphenyl 
Grignard reagent at room temperature to afford 77 by nucleophilic substitution (scheme 
2-22). The Grignard reagent was added dropwise to keep compound 74 in excess to 
prevent over addition and formation of the unwanted triaryl compound. A single peak 
shown in the 19F NMR spectrum occurred at -3 ppm chemical shift, which confirmed to the 
second substituted group. Although the first substitution of F in 1,3,5-trifluorotriazine 
occurs with a neutral nucleophile, replacement of the second of third fluorine requires an 
anionic organometallic reagent.
The failed reaction of 78 may be due to the lower reactivity of the 1,3-benzodioxole-5-yl 
group,  but there is no obvious reason for the lack of reaction. 
Product Product structure Reaction reagent Yield/(%)
77
Grignard 25
n-BuLi 22
78
Grignard
Only starting 
material 
recycled
n-BuLi
Only starting 
material 
recycled
 
 
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2.11 Synthesis of 2,4-chloro-6-monoaryl s-triazines
Cyanuric chloride 29, a cheaper and more readily available reagent than the 
corresponding fluride, was used as starting material in the next steps, and it would be less 
reactive than the fluoride one, which means the conditions would be more easily 
controlled.
The first aim of this part was to synthesis the monoaryl-substituted triazines. We obtained 
two 2,4-dichloro-6-monoaryl-s-triazines, 79 and 80, using nucleophilic substitution via a 
Grignard reagent or lithiation of a bromoarene with n-butyllithium as reagent (Scheme 
2-25).
 
                      29                      79 Ar: 2,4-dimethoxyphenyl
                                              80 Ar: 1,3-benzodioxole-5-yl
Scheme 2-25. Reagents and conditions: (a) Grignard reagent, anhydrous THF, 0˚C to r.t., 
overnight; (b) ArBr, n-BuLi, anhydrous THF, -78˚C to r.t., overnight.
The Grignard reagent was added dropwise to the solution of cyanuric chloride in 
anhydrous THF at 0 ˚C. The monoaryl-s-triazines were purified using column chromato-
graphy, where unreacted cyanuric chloride eluted at the very beginning owing to its non-
polar structure. As the cyanuric chloride was kept in excess and the temperature was 
controlled, the unwanted di-substitued by-product was avoided. 
From TLC analysis, 79 showed Rf=0.5 (eluent petroleum ether: ethyl acetate=4: 1), while 
80 was less polar and exhibited an Rf=0.8 (eluent petroleum ether: ethyl acetate=8: 1). 
After comparing the 1H NMR spectrum with the starting material, we confirmed the 
presence of more deshielded peaks in the aromatic region. Mass spectrometry also 
revealed the theoretical [M+H]+ isotopic signature with strong peaks at 286.0140 and 
269.9827 for the 35Cl2 isomers of compounds 79 and 80, respectively.
The products 79 and 80 were also obtained when the Grignard reagent was replaced by 
the aryllithium reagent. The n-BuLi reagent was introduced to the aromatic bromide at 
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-78˚C in anhydrous THF under nitrogen atmosphere to effect bromine-lithium exchange, 
and then stirred at room temperature for 30 minutes to complete the aryllithium formation. 
The reaction mixture was cooled to -78˚C again when the solution of cyanuric chloride 
introduced rapidly. 
Two methods used were listed in Table 2-5.
Table 2-5.
As a conclusion, 2,4-dichloro-6-(2,4-dimethoxyphenyl)-s-triazine 79 and 2,4-dichloro-6-
(1,3-benzodioxole-5-yl)-s-triazine 80 were both successfully prepared via Grignard reagent 
or using organolithium nucleophile as reagent, with both reactions giving the similar yields.
The yields were higher for the reaction of the Grignard and lithium reagents with the 
trichlorotriazine than the difluoro-monaryl system 74 most likely due to the presence of 
three halogens.
Structure code Product Reaction reagent Yield/(%)
79
Grignard 75
n-BuLi 73
80
Grignard 70
n-BuLi 62
 
 
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2.12 Synthesis of 2-chloro-4,6-diaryl s-triazines
Our next target was to join 2,4-dimethoxyphenyl and 1,3-benzodioxole-5-yl groups 
together forming a  2-chloro-4,6-diaryl-s-triazine 81 following the procedure discussed in 
section 2.11 (Scheme 2-26).
 
81
 
Scheme 2-26. Synthesis of 2-chloro-4,6-diaryl-s-triazine 81. Reagents and conditions: (a) 
Grignard reagent, Ar2Br, anhydrous THF, 0 ˚C to r.t., overnight; (b) n-BuLi, Ar2Br, (needs 
Ar2Br), anhydrous THF, -78˚C to room temperature, overnight.
We attempted to synthesis the target di-aryl-product and our attempts are listed in Table 
2-6.
N N
NCl Ar1
Cl
N N
NCl Ar1
Ar2
a or b
Entry Starting material Reaction reagent Yield/(%)
1 Grignard
Only 
starting 
material 
recycled 
 
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Table 2-6. Synthesis of 2-chloro-4,6-diaryl-s-triazine 81
Our fist attempt was to attach 1,3-benzodioxole-5-yl to the monoaryl compound, 2,4-
dichloro-6-(2,4-dimethoxyphenyl)-s-triazine 79, formed in section 2.11 using Grignard 
reagent. However, no new spots were shown after TLC tracking even when the reaction 
time was prolonged to 3 days. The lack of reaction was firstly ascribed to the lower activity 
of 1,3-benzodioxole-5-yl group. However, after the two aromatic group sequence swapped, 
new product spots were still not observed. 
It appeared the dichloro-mono-aryl triazines were considerably less reactive than the 
corresponding fluorides, or the room temperature could not allow the secondary chloride 
group substituted by the Grignard reagent. Reactions forming 79, or 80 gave around 70% 
yield, whereas 81 was formed in only 35% yield.
Then we decided to use the lithium reagent to achieve the nucleophilic substitution. The 
desirable compound 81 was successfully obtained as a yellow colored oil. 
From TLC analysis, compound 81 exhibited higher polarity than compounds 79 and 80. 
The 1H and 13C NMR spectra had confirmed the purity of the product. We also confirmed 
the product by mass spectrometry with a signal matching theoretical [M+H]+ value at 
372.0735.
2 Grignard
Only 
starting 
material 
recycled
3 n-BuLi 35
 
 
 
 
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 
82
Additionally, a triary-substitued triazine 82 was obtained with the previous procedure (entry 
3) after two equivalence of 2,4-dimethoxyphenyl bromide and Grignard reagent were 
introduced. 
From TLC analysis, compound 82 showed to be even more polar than 81. The 1H and 13C 
NMR spectra both confirmed the purity of the product. The signals of 2,4-dimethoxyphenyl 
group exhibited double intensity than that of 1,3-benzodioxole-5-yl group. We also 
confirmed the product by the matching theoretical [M+H]+ signal at 474.1660 in the high 
resolution mass spectrum.
Conclusion
As a conclusion, the first chloride atom on triazines 29 can be replaced smoothly using 
either Grignard or aryllithium reagent. The yields found were similar for the lithium and 
Grignard reagents, and there was little to choose between the methods, although the 
lithium arenes were easier to generate from a practical point of view, and represent the 
preferred methodology.
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2.13 Synthesis of monoamino-substitued s-triazines 
Recent studies have confirmed that several s-triazine derivatives bearing morpholine, 
piperidine and some piperazine moieties are effective against M. tuberculosis H37Rv 
strain.[93]
A series of (piperazinyl/piperidinyl)-s-triazine derivatives were prepared by Mewada et al., 
and the general procedure is shown in Scheme 2-27.[92]
 
Scheme 2-27. Mewada procedure. Reagents and conditions: (a) 4-ethynyl-benzenamie, 
NaHCO3, THF, r.t., 6 h, 85%; (b) 1-methylpiperazine, acetone, 56 ˚C, 4 h, 76%.
Patel and co-workers had synthesized a series thiazolidin4-one fused s-triazines as 
potential antimicrobial and anticancer agents.[93] 2,4-Dichloro-6-(4-methylpiperzin-1-yl)-s-
triazine 83 was initially constructed from N-methylpiperazine with 2,4,6-trichloro-s-triazine 
as shown in Scheme 2-28.
 
                                                 29                               83
Scheme 2-28. Patel procedure.[93] Reagents and conditions: (a) N-methylpiperazine, 
potassium carbonate, anhydrous acetone, 0 ˚C, 6 h, 89%.
2,4-Dichloro-6-morpholinyl-s-triazine 84 had been had been synthesized by Chuan and co-
workers from 2,4,6-trichloro-s-triazine and morpholine in the presence of sodium 
carbonate in water[94].
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                                                   29                               84
Scheme 2-29. Chuan procedure.[94] Reagents and conditions: (a) Morphline, sodium 
carbonate, water, 5 ˚C, 3 h, 77%.
The first aim of this part is to syntheses the monoamino-substitued-s-triazines using 
related methods. THF was employed be solvent because acetone can undergo side 
reactions in the presence of bases.
We obtained a series of compounds of monoamino-substitued-s-triazines 83-88 with the 
general procedure shown in Scheme 2-30. The products properties are summarized in 
Table 2-5.
 
                                               29                                         83-87
Scheme 2-30. Reagents and conditions: (a) amino reagent, THF, potassium carbonate, 0 
˚C, 8 h.
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Table 2-7. The monoamino-substitued-s-triazines 83-88.
The reactions of 2,4-dichloro-6-(4-methyl-1-piperazinyl)-s-triazine 83 and 2,4-dichloro-6-(4-
morpholinyl)-s-triazine 84 proceeded smoothly as reported and the products were obtained 
in good yield of 62% and 70%, respectively. Analytical and spectroscopic data were in 
Introduced amine Product Product structure Yield/(%)
1-Methylpiperazine 83 62
Morphline 84 70
1-Acetyl-piperazine 85 65
Cyclopentylamine 86 49
2-Pyridone 87 54
4-Pyridone 88 56
 
 
 
 
 
 
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agreement with that reported in literature[93,94].
Another experiment was attempted based on the reaction above. 1-Aceyl-piperazine, was 
introduced to the cyanuric chloride ring forming 2,4-dichloro-6-(4-acetyl-1-piperazinyl)-s-
triazine 85 as a colorless oil in good yield. From 1H NMR spectra, peaks due to protons 
from the piperazine ring were observed in similar region (ca. 2 and 3 ppm) compared to 
that of compound 83. A single peak at δ=2.00 p.p.m. corresponding to the methyl group 
was observed as well. 
Two more secondary amino derivatives, 2-pyridone and 4-pyridone, were also employed. 
As the pyridone anions were highly nucleophilic and could attached easily, TLC analysis 
showed two spots even when the reactions were run at 0 ˚C. For both reactions, the 
desired product gave different polarities with the by-product, and they were separated via 
column chromatography. Through analysis of the mass spectra, the signals of the desired 
products 87 and 88 were observed, and the signal of the by-product was also detected as 
the di-substitued compounds were also presented (nmono:di=5: 1). Through analysis of the 
1H NMR spectra, the products retained the same peak distribution as with the starting 
material (triplet, doublet, doublet and triplet in sequence from 2-pyridone one, and doublet 
and doublet in sequence from 4-pyridone one), but shifted to lower field region.
A commercial available primary amine, cyclopentylamine, was introduced to the triazine 
ring. The desire product was easily obtained as a colorless oil after aqueous work-up. IR 
spectroscopy was used, and one strong signal in presented NH stretch at ν 3335 cm-1 
region characterized that the primary amine group of starting material was no longer 
present. From the 1H NMR spectrum, signals due to protons from the cyclopentyl ring were 
more deshielded than that of the starting material. 
Conclusion
Cyanuric chloride 29 was treated with six commercially available amines. Based on 
procedures in literature,[93, 94] six monoamino-substituted s-triazine intermediates 83-88 
were successfully prepared. The products were sent to collaborators at De Montfort 
University for further bioactivity test. 
  / 62 156
2.14 Synthesis of 2-aryl-4-amino-disubstitued s-triazines
We also attempted to synthesis the 2-aryl-4-amino-disubstitued s-triazines 89-94 starting 
from the 2,4-dichloro-6-monoaryl-s-triazines 74, 77 and 78 synthesized previously (Table 
2-8).following the general procedure (Scheme 2-31).
 
Scheme 2-31. Synthesis of the 2,4-dichloro-6-monoaryl-s-triazines. Reagent and 
conditions: (a) amine, THF, potassium carbonate, r.t., 8 h.
N N
NF/Cl Ar
Cl
N N
NF/Cl Ar
NRR'
a
Starting 
material Introduced amine Product
Product

Structure
Yield/
(%)
74 Cyclopentylamine 89 50
79 Cyclopentylamine 90 45
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Table 2-8. Synthesis of the 2-aryl-4-amino-disubstitued s-triazines 89-94.
79 1-methylpiperazine 91 40
80 Cyclopentylamine 92 41
80 1-methylpiperazine 93 43
80 2-pyridone 94 40
 
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2,4-difluoro-6-(N,N-dimethylaminophenyl)-s-triazine 74 was treated with cyclopentylamine 
in the presence of triethylamine at room temperature. The reaction was run for 8 hours and 
the desired product was formed as a pale yellow colored oil. The 1H and 13C NMR proved 
this product to be pure. In IR spectroscopy, a single peak at n 3330 cm-1 representing the 
NH stretch also proved that the amine attached successfully and the secondary amine was 
formed.
The predicted of bioactivity score for 89 was analysed via http://www.molinspiration.com/, 
and showed it has potential uses as a GPCR ligand, kinase inhibitor or enzyme inhibitor.
As the fluoride compound 74 was very reactive, and the temperature or the reaction time 
may not controlled very well, a tri-substituted by-product was formed, which gave double 
intensity signals for the amine group in both 1H and 13C NMR spectra than that of 89.
We successfully synthesized and isolated the 2-aryl-4-amino-disubstitued s-triazines 90-94 
in fair yields. The products were confirmed to be pure using 1H NMR spectroscopy and MS 
spectrometry experiments. 
Conclusion
Three mono-aryl substituted s-triazines 74, 79 and 80 were treated with commercially 
available amines, and a series of 2-aryl-4-amino-disubstitued s-triazines 89-94 were 
formed successfully. In future, the reaction temperature and time may need to be 
controlled more accurately to optimize the yields and reduce by-product formation.
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Section 3:
A series of new target scaffolds were designed around the kinase inhibitor 38. Similar to 
the structure of ErbB family tyrosine kinase inhibitors in Figure 1-19, compound 38 
consisted of an aniline and piperazine solubilizing groups, but the quinazoline core is 
replaced by a  purine scaffold. It exhibits antitumor potency against the NSCLC cell line 
and drug resistance mutations. We wanted to make simpler analogues in fewer steps 
using our approach with SNAr reactions.[96]
38
Figure 2-3. Structure of optimized inhibitor 38.
To simplify the synthesis and improve conformational mobility, the imidazo ring of the 
purine core has been removed and a series of flexible amine substituents incorporated 
generating 95 and 100 as targets in this research.
       
95                                              100
Figure 2-4. Structure of 95 and 100.
The piperizinylphenylamino group is retained at the position corresponding to C-2 of the 
original purine ring. The amino substituents should be amenable to insertion by stepwise 
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SNAr reaction of an polyfluoropyridine core and will also to increase the number of sp3 
centers and the number of rotatable bonds both desirable in drug candidates.[95]
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2.15 Synthesis of 9-Cyclopentyl-N2-4(4-methylpiperazin-1-yl)phenyl)-N8-phenyl-9H 
-2,8-diamine 95
The first aim of this discussion is concerned with the synthesis of perfluoroarene 38. 
Pentafluoropyridine, as the structure core, was proposed to be substituted at the 4-, 2-, 6- 
and 5-positions sequentially (Scheme 2-32).
 
Scheme 2-32. Purposed synthetic route of perfluoroarene 95. Reagents: (a) Et3N; (b) 1-
methylpiperazine, K2CO3; (c) H2, Pd/C, EtOH (d) base; (e) protecting group; (f) N1-
cyclopentyl-N2-phenyl-1,2-enhaediamine; (g) protecting group removal.
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Starting with commercially available pentafluoropyridine, cyclopentylamine would be 
attached at the para-position of the pyridine ring to provide N-cyclopentyl-2,3,5,6-
tetrafluoro-4-pyridinamine 96. 4-(4-Methylpiperazin-1-yl)-phenylamine 40 was then be 
added, with nucleophilc substitution expected to occur at the next most reactive site, the 
ortho position, forming the intermediate 97. In order to attach the  N1-phenyl-1,2-
ethanediamide group on meta position, a protecting group for the ortho position was 
considered necessary in procedure. This approach would generate a new set of test 
compounds which would be screened for anti-cancer activity, and their properties 
compared to the original inhibitor compound 38.
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2.16 Synthesis of N-cyclopentyl-2,3,5,6-tetrafluoro-4-pyridinamine 96
Our first target was the N-cyclopentyl-2,3,5,6-tetrafluoro-4-pyridinamine 96 (Scheme 
2-33).
   
                                                                                                                  96
Scheme 2-33. Synthesis of compound 96. Reagents and conditions: (a) Et3N, CH3CN, 
0˚C, 8 h, 80%. 
Polyfluorinated aromatic systems have an interesting ‘mirror-image’ relationship with the 
corresponding hydrocarbon compounds, in that the former generally react with 
nucleophiles, via Meisenheimer complexes[67] that undergo electrophilic substitution, as 
shown in Figure 2-5.
 
                                            Meisenheimer intermediate
Figure 2-5. ‘Mirror-image’ chemistry, X=H, CN, OCH3, etc.
Nucleophilic attack occurs predominantly para- to the substituent X in pentafluorobenzene 
derivatives, regardless of whether the substituent is electron-withdrawing, hydrogen, or 
electron-donating[76].
We obtained compound 96 following this observation. The reaction proceeded smoothly 
and pure product was obtained as a pale yellow liquid. On comparing with the 1H spectrum 
of cyclopentylamine, the product signals have become deshielded resulting in a downfield 
shift of 0.8 p.p.m.. In the 13C NMR spectrum, the symmetry of the molecule was apparent. 
Two very strong signals at δ = 34.7 and 23.7 p.p.m. belong to the two pairs methylene 
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groups of the cyclopentyl moiety. In the aromatic region, a double triplet peak at 144.3 
p.p.m. and a double doublet signal at 130.9 p.p.m. belong to the two pairs of carbons 
bonded to fluorine, which give 1JC-F coupling constants of 236 and 244 Hz, respectively 
(Figure 2–6). 
Figure 2-6. C-F coupling in compound 96: partial 13C NMR spectrum (CDCl3)
In 19F NMR spectroscopy confirmed the structure by the presence of multiplet peaks at 
ranges -2.5 and -67.5 ppm representing the two mirror-imaged pairs of fluorine groups 
from the fluoropyridine ring respectively. 
2.17 Synthesis of 1-(4-aminophenyl)-4-methylpiperazine 40
The 1-(4-aminophenyl)-4-methylpiperazine 40 was prepared according to a literature 
procedures (Scheme 2-34)[20].
4-Fluoronitrobenzene was treated with methylpiperazine in the presence of potassium 
carbonate to produce the intermediate 1-methyl-4-(4-nitrophenyl)piperazine in good yield. 
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The nitro group was catalytically hydrogenated over palladium on carbon (Pd/C) to 
provided the desired aniline in excellent yield.
 
Scheme 2-34. Synthesis of 1-methyl-4-(4-nitrophenyl)piperazine 39 and 4-(4-
methylpiperazin- 1-yl)phenylamine 40. Reagents and conditions: (a) 1-methylpiperazine, 
K2CO3, DMSO, r.t., 6 h, 95%; (b) H2, 10% Pd/C, EtOH, r.t., 9 h, 90%.
We obtained 1-(4-aminophenyl)-4-methylpiperazine 40 successfully by a 2-step reaction 
(Scheme 2-35) with modified conditions to the literature method.
 
                                                                        39                               40
Scheme 2-35. Synthesis of 1-methyl-4-(4-nitrophenyl)-piperazine 39 and 1-(4-amino-
phenyl)-4-methylpiperazine 40. Reagents and conditions: (a) 1-methylpiperazine, Et3N, 
CH3CN, 82 ˚C, 8 h, 90%; (b) H2, 10% Pd/C, 1 atmosphere, HPLC grade MeOH, 25 ˚C, 10 
h, 99%.
The signals in the 1H and 13C NMR spectra of compound 40 matched the reference data. 
Compound 39 was yielded as a yellow colored solid, which was soluble in water. Thus the 
volume of the aqueous phase was minimized in extraction step. Compound 40 was yielded 
initially as a colorless solid but presented a problem with stability, as the material would 
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turn black after only 10 minutes in contact with air. It was thought that aerial oxidation of 
the electron rich arene was occurring leading to decomposition.
Then we aimed to introduce 1-(4-aminophenyl)-4-methylpiperazine 40 at the ortho-position 
on the pyridine ring in N-cyclopentyl-2,3,5,6-tetrafluoro-4-pyridinamine 96.
 
Scheme 2-36. Synthesis of scaffold 97.
As the substitution reaction at the para-position fluoride had proceeded smoothly at 0 ˚C 
and gave a good yield, the reaction was firstly run at room temperature for 8 hours. After 
analysis with TLC plate, however no new spot presented. After aqueous work-up and 
analysis by 1H NMR spectroscopy, the signals were found to be the same as those of the 
starting material.
The reaction was then run with a stronger base (sodium hydride) at higher reaction 
temperature (82 ˚C). Gas evolution occurred at the beginning of the reaction, which 
indicated that compound 40 was deprotonated with sodium hydride. Unfortunately, the 
substitution reaction still did not occur.
The crude product presented the same 1H NMR spectrum as the starting material 40.
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2.18 Synthesis of 4-(4-acetylpiperazin-1-yl)-aniline 101[86]
A scaffold of 1-(4-aminophenyl)-4-methylpiperazine 40 was also synthesized by replacing 
the piperazine methyl group by an acetyl group. The 4-(4-acetylpiperazin-1-yl)-aniline 101 
was successfully obtained by a 2-step reaction between fluoronitrobenzene and N-
acetylpiperazine (Scheme 2-37).
 
                                                                      102                              101
Scheme 2-37. Synthesis of 4-(4-acetylpiperazin-1-yl)-aniline 101. Reagents and 
conditions: (a) Et3N, CH3CN, 82 ˚C, 8 h, 95%; (b) H2, 1 atmosphere, HPLC grade 
methanol, 25 ˚C, 10 h, 99%.
The 1H and 13C NMR spectra both indicated the product to be pure. The spectra gave 
similar signals to that of compound 40 and a new signal representing the methyl group.
Following the procedure discussed in section 2.17, the reaction was allowed to run with 
sodium hydride at a higher reaction temperature (120 ˚C) after the solvent was changed to 
DMF.
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                        
Scheme 2-38. Synthesis of N-cyclopentyl-2-[4-(4-acetylpiperazin-1-yl)-anilino]-3,5,6-
trifluoro-4-pyridinamine.
Unfortunately again, there was no new product formed, and substitution at the 2-position, 
normally straightforward, appeared compromised by the electron donating amine 
substituent at C-4.
Conclusion 
An advanced intermediate, N-cyclopentyl-2,3,5,6-tetrafluoro-4-pyridinamine 96, and two 4-
(4-piperazin-1-yl)-anilines 40 and 101 were produced smoothly in good yields. Although 
the solvent conditions and base were investigated extensively, the desired 2-position 
substitution reaction proved difficult and the synthesis of the final target compound could 
not be completed.  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2.19 Synthesis of 2,3,5,6-tetrafluoro-N-4-substitued pyridianamines 103 and 104 
As mentioned in the section of orientation reactions in polyfluorinated compounds, 
nucleophilic substitution of fluorine in pentafluoropyridine occurs initially almost exclusively 
at the para-position. Afterwards at the ortho- and meta-position in turn.
It was expected that cyclepentylamine would attack at the ortho-position more easier than 
two piperizinylphenylamines 40 and 101 prepared above. We aimed to make analogues of 
compound 96 , which have the piperzinylphenylamino groups substituted at para-position.
We thus obtained 2,3,5,6-tetrafluoro-N-4-(4-methyl-1-piperazinyl)phenyl-4-pyridinamine 
103 and 2,3,5,6-tetrafluoro-N-4-(4-acetyl-1-piperazinyl)phenyl-4-pyridinamine 104 
according to the procedure mentioned in section 2.16 (Scheme 2-39).
 
                                                                                                                                            103: R=CH3           
                                                                                                                                            104: R=COCH3                                
Scheme 2-39. Synthesis of 103 and 104. Reagents and conditions: (a) Et3N, CH3CN, 0 ˚C, 
8 h, 70% and 73%, respectively.
The reactions were both proceeded smoothly and pure products were obtained as fine 
white colored powder. The melting points were both increased by 70 ˚C compared to 
starting material; 103 (168 ˚C) and 104 (194 ˚C) with 40 (94 ˚C) and 96 (130 ˚C).
The 1H and 13C NMR spectra indicated the products to be pure. 19F NMR spectroscopy 
confirmed this by the presence of multiplet peaks representing of two mirror-imaged pairs 
of fluorine groups from the fluoropyridine ring respectively.
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We aimed to attach the cyclopentylamine to the ortho-position (C-2) of the pyridine ring in 
103 and 104 prepared previously (Scheme 2-40). The reactions were run with the 
following conditions (Table 2-9).
 
                                                                                                                                            103: R=CH3           
                                                                                                                                            104: R=COCH3          
Scheme 2-40.
Table 2-9.
We were unsuccessful in our attempts even though the base was changed in sequence, 
the reaction temperature was increased while the reaction time was prolonged. After 
analysis by TLC, no new spot presented. After aqueous work-up and analysis by 1H NMR 
spectroscopy, the signals were found to be the same as those of the starting material.
Conclusion
Two 4-(4-piperazin-1-yl)-anilines 40 and 101 were attached to position-4 giving the 
analogues 103 and 104 both in good yields. Cyclopentylamine with less steric bulk was 
attempted to be attached at position-2, but the reactions were still unsuccessful. 
a
N
F F
F F
HN
+ x
N
N
R
N
F F
F NH
HN
N
N
R
NH2
Entry Solvent Base Reaction temperature/(˚C)
Reaction 
time/(hours)
1 Acetonitrile Triethylamine 23 8
2 Acetonitrile Sodium amide 40 72
3 Cyclopentylamine Sodium hydride 40-100 24
4 TFE/TFA — 100 48
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It was supposed that the secondary amine group in compounds 96, 103 and 104 had 
blocked the next steps reactions. Thus, we decided to modify the primary amines with the 
4-toluenesulfonyl group to improve acidity and reactivity.
2.20 Synthesis of 4-toluenesulfonyl protected secondary amines 105 and 106
The primary amines cyclopentylamine and 40 were treated with 4-toluenesulfonyl chloride, 
and gave the expected products 105 and 106. The reactions proceeded successfully and 
the products could easily isolated after aqueous workup (Scheme 2-41).
 
                                                                                                   105
 
                                                                                                    106
Scheme 2-41. Synthesis of 105 (above) and 106 (bottom). Reagents and conditions: (a) 
pyridine, DCM, 0 ˚C, 8 h, 72% and 68, respectively. 
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N-cyclopentyl-4-methyl-benzenesulfonamide 105 was prepared by Pei and co-workers by 
another route (Scheme 2-42).[97]
 
Scheme 2-42. Pei procedure. Reagents and conditions: (a) HOTf-SiO2, H2O, toluene, 20 
h, 85 ˚C, 84%.
The melting point and 1H NMR spectroscopy of our product 105 were in agreement with 
that reported in the literature.
For compound 106, 1H NMR spectroscopy, the doublet peaks at 7.57, 7.18, 6.94 and 6.74 
ppm corresponding to the four pair aromatic protons were observed. Two singlet peaks at 
2.43 and 2.35 ppm corresponding to the protons of the methyl groups at both ends of the 
structure respectively.
2.21 Synthesis of N-cyclopentyl-4-methyl-N-(2,3,5,6-tetrafluoropyridin-4-yl) benzene- 
1-sulfonamide 107
According to the procedure mentioned in scheme 2.16, the secondary amine we made 
above, N-cyclopentyl-4-methyl-benzenesulfonamide 105, was treated with pentafluoro-
pyridine in the presence of sodium hydride, and gave the expected product in 107 good 
yield (Scheme 2-43).
  
Scheme 2-43. Synthesis of 107. Reagents and conditions: (a) NaH, CH3CN, 0 ˚C, 8 h, 
80%.
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The fluoropyridine ring was attached successfully, which was identified by the 19F NMR 
spectroscopy by the presence of multiplet peaks at -5.80 and -57.3 ppm representing of 
two mirror-imaged pairs of fluorine groups.
With the compounds 106 and 107 modified with 4-toluenesulfonyl group, the ortho position 
substitution reaction was attempted with the reaction conditions below (Scheme 2-44). 
However, the reaction was unsuccessful. 
After analysis by TLC, no new spot again was observed. After aqueous work-up and 
analysis by 1H NMR spectroscopy, the signals were found to be the same as those of the 
starting material.
 
Scheme 2-44. Synthesis of 3,5,6-trifluoro-2,4-disubsttitued-pyridinamine. Reagent and 
condition: (a) Sodium hydride, DMF, 100 ˚C, 24 h.
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Instead of 4-toluenesulfonyl chloride, in next multistep reaction sequence, an acid 
anhydride, propionic anhydride, was employed as a common acyl source because of its 
ready availability and stability. 
2.22 Synthesis of N-cyclopentyl-propanamide 108 and N-[4-(4-methyl-1-piperazinyl) 
phenyl]-propanamide 109
Andrea and co-workers described a mild and convenient procedure for the N-acylation of 
different amines with anhydrides in ethyl acetate at room temperature[98]. The products 
were formed cleanly and do not require chromatographic purification. 
 
Scheme 2-45. Acylation of amines with anhydrides[98]. Reagents and conditions: (a) N2 
protection, ethyl acetate, potassium carbonate, room temperature, 6 h, 98%.
Following the relative procedure, we modified our two moieties with propionic anhydride 
and obtained the desired product N-cyclopentyl-propanamide 108 and N-[4-(4-methyl-1-
piperazinyl)phenyl]-propanamide 109 both in excellent yield (Scheme 2-46).
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 
                                                                  109
Scheme 2-46. Synthesis of N-cyclopentyl-propanamide 108 and N-[4-(4-methyl-1-
piperazinyl)phenyl]-propanamide 109. Reagents and conditions: (a) N2 protection, 
potassium carbonate, pyridine, dichloromethane, room temperature, 85% and 90%, 
respectively.
Cyclopentylamine was treated with propionic anhydride in the presence of potassium 
carbonate under nitrogen protection, and after aqueous workup the expected product 108 
was easily isolated in excellent yield. The reaction was exothermic, thus it was started at 0 
˚C and then warmed to room temperature. In IR spectroscopy, a single signal at 3325 was 
observed.
1-(4-Aminophenyl)-4-methylpiperazine 40 was treated with propionic anhydride in the 
presence of potassium carbonate under nitrogen protection, and after aqueous workup the 
expected product 109 was easily isolated in excellent yield. In 1H NMR spectroscopy, this 
was confirmed by the presence of new quartet peaks at 2.35 ppm and triplet peaks at 1.23 
ppm corresponding to the protons of the ethyl groups of the propionic group attached. The 
product was far more stable than the starting material, and did not turning into black color 
anymore.
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2.23 Synthesis of analogues 110 and 111
The acylated products 110 and 111 were then attached to pentafluoropyridine ring 
following the procedure discussed previously (Scheme 2-47).
 
                                                          108                                       110
 
                                                        109                                        111
Scheme 2-47. Synthesis of 110 and 111. Reagents and conditions: (a) NaH, CH3CN, 0˚C, 
8 h, 75% and 70%, respectively.
Compounds 110 and 111 were both produced smoothly without any problems like the 
para-substituted pentafluoropyridine 96 synthesized previously. The melting point of both 
products were increased as 40 and 103. In 19F spectroscopy, two multiplet peaks 
observed, (-63.86/-7.85 p.p.m. and -80.36/-43.26 for 110 and 111, respectively)  
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The ortho-substitution reaction was then tried with the modified products synthesized 
above (Table 2-10) following the conditions tried previously (Scheme 2-48).
 
Scheme 2-48. Synthesis of 2,4-disubstituted-pentafluoropyridine (entry 1).
Table 2-10.
The reactions were not started Unfortunately, no expected product isolated in any 
reactions, neither the substrates and the reactants were modified with the propionic 
anhydride.
Conclusion
The amine and aniline groups were protected with 4-toluenesulfonyl or propionic 
anhydride, giving more acidic compounds 105, 106, 108 and 109, and these were 
attached at position-4 forming 107, 110 and 111 without any problem. However, these 
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Entry Substrate Reactant Product yield
1 96 109 Only starting material recovered
2 111 Cyclopentylamine Only starting material recovered
3 110 109 Only starting material recovered
4 111 108 Only starting material recovered
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compounds were still not able to substitute the fluorine at position-2 in attempted base 
catalysed reactions.
2.24 Synthesis of perfluoroarene 100
The second target of this discussion was aimed to synthesis of perfluoroarene 100 
(Scheme 2-49).
 
Scheme 2-49. Proposed synthesis route to perfluoroarene 100. Reagents and conditions: 
(a) dichloromethane, MgSO4; (b) dichloromethane, sodium borohydride; (c) acetonitrile, 
triethylamine.
The synthesis of perfluoroarene 100 would require making the diamine, N1-cyclopentyl-N2-
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phenyl-1,2-ehanediamine 112 by reductive amination of cyclopentanone with the 
phenylethylene diamine (Scheme 2-48) and reacting that with pentafluoropyridine first (to 
add at the para-position), and then adding the piperazinyl aniline 40 in sequence (so it 
adds at the ortho-position of the pyridine ring.
2.25 Synthesis of N1-cyclopentyl-N2-phenyl-1,2-ehanediamine 112
N1-cyclopentyl-N2-phenyl-1,2-ehanediamine 26 was successfully synthesized by a 2-step 
reaction (Scheme 2-50).
 
                       113                                                  114                                    112
Scheme 2-50. Synthesis of N1-cyclopentyl-N2-phenyl-1,2-ehanediamine 112. Reagents 
and conditions: (a) cyclopentanone, MgSO4, DCM, r.t., 8 h, 70%; (b) NaBH4, EtOH, room 
temperature, 8 h, 76%.
N-Pheylethylenediamine 113 was treated with cyclopentanone in the presence of 
magnesium sulphate, and gave the expected imine 114 in good yield. The magnesium 
sulphate was added to avoid the reversion, and the filtration was conducted under gravity 
in order that the water formed could be kept in the dessicant residue. On comparing the IR 
spectrum with that of the starting material, two NH absorptions at 3291 cm-1 were seen to 
have disappeared. In the 1H NMR spectrum, signals representing protons on the benzyl 
ring and cyclopentyl rings were observed in the correct ratio.
As the intermediate 114 was unstable and recent to the amine by hydrolysis, it was 
reduced with sodium borohydride, and gave the expected product 112 in good yield. In the 
1H spectrum, a new peak at δ 3.08 was observed, which represents the -CH in cyclopentyl 
ring indicating that the double bond was reduced successfully.
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2.26 Synthesis of N1-cyclopentyl-N2-phenyl-N1-(2,3,5,6-tetrafluoropyridin-4-yl)ethane 
-1,2-diamine 115
The aniline nitrogen of the phenylethylene diamine should be much less nucleophilic than 
the alkyl amine group so it was hoped that alternatively substituted by-products would not 
be formed.
 
                         112                                                                                115
Scheme 2-51. Synthesis of 115. Reagents and conditions: (a) NaH, CH3CN, 0 ˚C, 8 h, 
70%.
N1-cyclopentyl-N2-phenyl-1,2-ehanediamine 112 was treated with pentafluoropyridine in 
the presence of sodium hydride, and gave the expected product 115 in good yield. In the 
1H spectrum, signals for the protons at two CH2 group and the cyclopentyl ring moved the 
chemical shift downfield by 0.4 p.p.m. as the secondary amine was transformed to the 
tertiary amine and they were more deshielded than the starting material.
N
F F
F F
FHN
HN
+
N
F F
F F
N
H
N
+
a
  / 87 156
Compound 115 was then used as the substrate in next step to form the 2,4-disubsttitued- 
3,5,6-trifluoropyridinamine (Scheme 2-52).
 
Scheme 2-52. Synthesis of 2,4-disubsttitued-3,5,6-trifluoropyridinamine
Unfortunately, the reactions were not started neither. After tracking by TLC, the product 
gave similar polarity with the starting material. In the 1H spectrum, signals representing the 
piperazine were not observed.
Conclusion
In this section, we aimed to prepare the perfluoroarene 95 as an alternate scaffold of the 
kinase inhibitor 38. The amine moiety 112 was successfully isolated. Then it replaced the 
position-4 fluorine atom on pentafluoropyridine smoothly to give compound 115 in good 
yield. Unfortunately, the desired substitution reactions at position-2 proved difficult and 
were still unsuccessful.
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Chapter 3: Conclusion
In section 1, we hoped to initially prepare the revised structure of the natural product 
acremolin, compound 52. During this time, the first total synthesis of the desired structure 
was reported, so then we continued our synthesis with a alternative synthetic route. The 
imidazopurine core was disconnected into two separate imidazole precursors 61 and 62. 
These two compounds were both successfully synthesized and isolated, but the yields 
were very poor. The coupling reaction between these two precursors could not be 
achieved, but may run in future research. We also prepared two analogues of the revised 
structure of acremolin, 68 and 69 as potential biologically active compounds. Three 
analogues of the imidazole precursors 70-72 were also prepared in order to synthesis 
further analogues in the future.
In section 2, we developed three mono-aryl, two di-aryl and one tri-aryl substituted s-
triazines, compounds of interest as potential anticancer agents. In addition, a number of 
commercially available primary (e.g. cyclopentylamine) and secondary (e.g. morpholine) 
amines were also attached to the s-triazines, giving six mono-amino, six mono-aryl-mono-
amino, two di-amino and two mono-aryl-di-amino s-triazines. A number of these 
compounds are currently undergoing screening for biological activity.
In section 3, we prepared three N-2,3,5,6-tetra-4-pyridinamine analogues 96, 103 and 104 
as potential kinase inhibitors. However, the desired substitution reactions at position-2 
proved difficult and were still unsuccessful. The amine moieties were then modified with 
either 4-toluenesulfonyl or propionic anhydride, giving the more acidic secondary amides 
105, 106, 108 and 109. Unfortunately, these modified compounds were only able to 
replace the fluoride at position-4 of the fluoropyridine ring in base catalysed SNAr 
reactions.
  / 89 156
Chapter 4: Experimental
Section 1: General experimental
Anhydrous conditions were obtained using oven/flame dried glassware purged with 
nitrogen prior to the addition of chemical reagents.  A nitrogen atmosphere was maintained 
throughout reactions where necessary through the use of a nitrogen balloon.  
Commercially available solvents were used and not subjected to further purification, 
except THF which was distilled as needed from sodium and benzophenone.  DMSO-d6 
was purchased dry from commercial suppliers.  Petroleum ether refers to the fractions with 
a boiling point between 40-60°C. Sodium hydride refers to a 60% dispersion of NaH in 
mineral oil. 
NMR spectra were recorded (1H, 13C and 19F) using a Bruker or Jeol 400MHz NMR 
machines.  Chemical shifts are reported in ppm for both forms of spectra.  1H spectra were 
recorded at 400MHz, 13C spectra were recorded at 100MHz and 19F spectra were 
recorded at 376MHz.  DEPT analysis was used to assign environment (CH, CH2, CH3) to 
each carbon atom in the 13C spectra.  The solvent system used for NMR measurements is 
specified in brackets. 
A Thermofisher executive (orbi) resolution mass spectrometer was used to obtain high 
resolution mass spectra, with ESI as the ionization source, or these were recored at the 
UK National Mass Spectometry Facility in Swansea.  The solvent used for all samples was 
methanol. 
Analysis by GCMS utilized a Fisons GC 8000 series (AS 800), using a 15 m x 0.25 mm 
DB-5 column and an electron-impact low resolution mass spectrometer.
IR spectra were obtained on FTIR-8400s.
TLC analysis was carried out on Merck TLC silica gel 60 F254 aluminum backed plates and 
were visualized by vanillin stain or under UV light at 254nm using a UVP chromato-vue 
cabinet model CC-60. Column chromatography used Apollo Scientific ZEOprep 60 silica 
with a particle size of 40-63 microns.  
The eluent and concentration used is specified in brackets. 
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Melting points were recorded using an Electrothermal-IA 9100 melting point instrument 
and are uncorrected.
Concentration of the Grignard reagents and n-BuLi were measured by diphenylacetic acid 
titration. 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Section 2: experimental for purine analogues
Synthesis of 2’,3’,5’-acetyl-guanosine[73]
 
48
A mixture of guanosine 8 (2.83 g, 0.01 mol), pyridine (0.25 mL, 0.03 mol) and DMF (0.25 
mL) was stirred in acetic anhydride (10 mL, 0.10 mol) at 100 ˚C for 2 hours. The reaction 
mixture was quenched with deionized water (70 mL). Then it was cooled to room 
temperature and extracted with dichloromethane (3 x 30 mL). The combined organic 
phases were washed with saturated sodium hydrogen carbonate solvent (3 x 20 mL) and 
brine, dried over magnesium sulfate. After filtration and purification via column 
chromatography (elution with methanol: ethyl acetate=1: 10), the title compound was 
yielded as a white fine powder (3.07 g, 0.0075 mmol, 75%, m.p. 223 ˚C, literature[73] 225 
˚C).
δH (400 MHz, DMSO-d6) 10.72 (s, br, 1H, NH), 7.93 (s, 1H, NCHN), 6.53 (s, br, 2H, NH2), 
5.98 (d, J = 6 Hz, 1H, CH-N in ribose), 5.80 (t, J = 6 Hz, 1H, CH-O in ribose), 5.49 (t, J = 6 
Hz, 1H, CH-O in ribose), 4.41-4.37 (m, 1H, CH-C in ribose), 4.34-4.29 (m, 2H, OCH2), 
2.04-2.02 (s, 9H, CH3)
δC (100 MHz, DMSO-d6) 170.41, 172.63, 172.49, 156.82, 154.25, 151.46, 135.97, 117.12, 
84.68, 79.79, 72.41, 70.74, 63.02 (CH2), 20.91, 20.68, 20.55.
HRMS m/z 410.1315. (C16H20N5O8+ requires 410.1312).
NH
N
N
O
NH2N
O
OO
O


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Synthesis of 2’,3’,5’-tripropanoate-guanosine
 
49
A mixture of guanosine 8 (2.83 g, 0.01 mol), pyridine (0.25 mL, 0.03 mol) and DMF (0.25 
mL) was stirred in propionic anhydride (12.5 mL, 0.10 mol) at 100 ˚C for 2 hours. The 
reaction mixture was quenched with deionized water (70 mL). Then it was cooled to room 
temperature and extracted with dichloromethane (3 x 30 mL). The combined organic 
phases were washed with saturated sodium hydrogen carbonate solvent (3 x 20 mL) and 
brine, dried over magnesium sulfate. After filtration and purification via column 
chromatography (elution with methanol: ethyl acetate=1: 10), the title compound was 
yielded as a white fine powder (3.16 g, 0.007 mmol, 70%, m.p. 218 ˚C). 
νmax (KBr,cm-1) 3433, 3310, 3187, 2739, 2292, 1751, 1697, 1607, 1535, 1481, 1381.
δH (400 MHz, DMSO-d6) 10.78 (s, br, 1H, NH), 7.93 (s, 1H, NCHN), 6.58 (s, br, 2H, NH2), 
5.99 (d, J = 6 Hz, 1H, CH-N in ribose), 5.82 (t, J = 6 Hz, 1H, CH-O in ribose), 5.54 (t, J = 6 
Hz, 1H, CH-O in ribose), 4.41-4.38 (m, 1H, CH-C in ribose), 4.38-4.34 (m, 2H, OCH2), 
2.43-2.32 (m, 6H, CH2), 1.08-0.97 (m, 9H, CH3).
δC (100 MHz, DMSO-d6) 173.34, 172.63, 172.49, 156.62, 153.85, 151.06, 135.57, 116.79, 
84.52, 79.59, 72.06, 70.24, 63.02 (CH2), 26.60 (CH2), 26.54 (CH2), 26.36 (CH2), 8.84, 
8.82, 8.71.
HRMS m/z 452.1787. (C19H26N5O8+ requires 452.1798). 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Synthesis of 2',3',5'-tripropanoate-N-(2-chloroacetyl)-guanosine
 
51
A mixture of 2',3',5'-tripropanoate-guanosine 49 (0.45 g, 1 mmol) and N-
ethyldiisopropylamine (0.34 mL, 2 mmol) was stirred in anhydrous THF (10 mL) for 0.5 
hours. Chloroacetyl chloride (0.16 mL, 2 mmol) was then added dropwise and the reaction 
mixture was stirred at 65 ˚C for a further 2 hours. The reaction mixture was cool to room 
temperature and treated with deionized water (20 mL) and extracted with ethyl acetate (20 
x 3 mL). The organic layer was washed with brine and dried over magnesium sulfate. After 
filtration and purification via column chromatography (elution with methanol: ethyl 
acetate=1: 10), the title compound was yielded as yellow oil (0.38 g, 0.68 mmol, 68%).
νmax (KBr,cm-1) 3394, 3202, 2947, 1743, 1589, 1373, 1180, 1087, 902, 786, 640;
δH (400 MHz, DMSO-d6) 11.92 (s, br, 1H, NH), 10.38 (s, br, 1H, NH), 7.83 (s, 1H, NCHN), 
6.09 (d, J = 6 Hz, 1H, CH-N in ribose), 5.84 (t, J = 6 Hz, 1H, CH-O in ribose), 5.51 (t, J = 6 
Hz, 1H, CH-O in ribose), 4.42-4.29 (m, 3H, OCH2 and -CH next to it), 4.36 (s, 2H, CH2-Cl), 
2.44-2.32 (m, 6H, CH2), 1.09-1.00 (m, 9H, CH3).
δC (100 MHz, DMSO-d6) 173.34, 172.63, 172.46, 168.94, 154.71, 148.34, 147.44, 138.06, 
120.71, 84.70, 79.88, 72.19, 70.17, 62.98 (CH2), 43.04 (CH2), 26.60 (CH2), 26.54 (CH2), 
26.33 (CH2), 8.84, 8.82, 8.69.
HRMS m/z 528.1491. (C21H2735ClN5O9+ requires 528.1495). 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Synthesis of 2’3’5’-tripropanoate-N-(2-chloroacetyl)-1-methyl-guanosine
 
52
A mixture of 2’,3’,5’-tripropanoate-N-(2-chloroacetyl)-guanosine 51 (put compound 
numbers into experimental) (1.06 g, 2 mmol) and iodomethane (0.24 mL, 4 mmol) was 
stirred in anhydrous THF (10 mL) at 40 ˚C for 4 hours. The reaction mixture was cool to 
room temperature and treated with deionized water (20 mL) and extracted with 
dichloromethane (20 x 3 mL). The organic layer was washed with brine and dried over 
magnesium sulfate. After filtration and purification via column chromatography (elution with 
methanol: ethyl acetate=1: 10), the title compound was yielded as yellow solid (0.51 g, 
0.92 mmol, 46%, m.p. 190 ˚C).
δH (400 MHz, DMSO-d6) 10.27 (s, br, 1H, NH), 7.89 (s, 1H, NCHN), 5.98 (d, J = 6 Hz, 1H, 
CHN in ribose), 5.91 (t, J = 6 Hz, 1H, CHO in ribose), 5.67 (t, J = 6 Hz, 1H, CHO in ribose), 
4.68, 4.48-4.42 (m, 3H, OCH2 and CH in ribose), 3.30 (s, 2H, CH2Cl), 3.28 (s, 3H, NCH3), 
2.46-2.37 (m, 6H, CH2), 1.21-1.14 (m, 9H, CH3).
δC (100 MHz, DMSO-d6) 173.33, 172.62, 172.51, 168.94, 154.72, 148.33, 147.44, 138.08, 
120.72, 84.72, 79.88, 72.19, 70.17, 63.00 (CH2), 43.04 (CH2), 32.98, 26.60 (CH2), 26.53 
(CH2), 26.32 (CH2), 8.84, 8.82, 8.71.
HRMS m/z 542.1643. (C22H2935ClN5O9+ requires 542.1648).
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Synthesis of 1-bromo-3-methyl-2-butanone[76]
 
56
To a solution of 3-methyl-2-butanone (2.12 mL, 20 mmol) in ice-cold methanol (10 mL) was 
added bromine (1.00 mL, 20 mmol) dropwise. The reaction mixture was stirred at 0 ˚C for 
2 hours, and then it was quenched with a solution of sodium hydrogen carbonate  (1 g) 
and sodium hydrogen sulfite (1 g) in deionized water (30 mL). After extraction with diethyl 
ether (3 x 20 mL) the organic layer were combined, washed with brine and dried over 
magnesium sulfate. After filtration and the solvent was evaporated the title compound was 
yielded as pale yellow liquid (3.14 g, 19 mmol, 95%).
δH (400 MHz, CDCl3) 4.00 (s, 2H, CH2Br), 2.98 (septet, J = 7 Hz, 1H, CH), 1.16 (d, J = 7 
Hz, 6H, CH3).
δC (100 MHz, CDCl3) 205.80 (CO), 38.36, 33.71 (1C, CH2), 18.49 (2C, CH3).
GCMS m/z 163.9. (C5H979BrO requires 163.9).
O
Br
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Synthesis of 4-isopropyl-2-methylthio-1H-imidazole
 
62
To a solution of S-methylisothiourea hemisulfate salt (1.39 g, 10 mmol) and sodium 
hydride (1.20 g, 30 mmol) in DMF (3 mL) was added a diluted solution of 1-bromo-3-
methyl-2-ketone 56 (1.65 g, 10 mmol) in DMF (1 mL) dropwise. The reaction mixture was 
stirred at room temperature for 8 hours. Then it was quenched with ethanol (2 mL), and 
neutralized with 1M HCl till the pH reached slightly higher than 7. After extration with 
deionized water (20 mL) and diethyl ether (3 x 20 mL), the organic layer were combined, 
washed with brine and dried over magnesium sulfate. After filtration and purification via 
column chromatography (elution with petroleum ether: ethyl acetate=1: 5) the title 
compound was yielded as yellow oil (0.24 g, 0.72 mmol, 16%).
δH (400 MHz, CDCl3) 9.21 (s, br, 1H, NH), 6.30 (s, 1H, NCH), 2.83 (septet, J = 6 Hz, 1H, 
CH), 1.32 (s, 3H, SCH3), 1.20 (d, J = 6 Hz, 6H, CH3).
δC (100 MHz, CDCl3) 159.36, 145.81, 118.77, 26.17, 23.34, 21.34 (2C, CH3).
HRMS m/z 157.2552. (C7H13N232S+ requires 157.2561).
N NH
S
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Synthesis of 4,5-diiodo-1H-imidazole[77]
 
66
To a solution of imidazole (3.40 g, 50 mmol) and sodium hydroxide (8.00 g, 200 mmol) in 
deionized water (30 mL) was added a solution of iodine (12.69 g, 50 mmol)  in hexane (30 
mL) dropwise. The reaction was stirred at room temperature for 8 hours. Then it was 
quenched with 1M HCl till the pH reached slightly higher than 7. After filtration and 
recrystallized with diluted ethanol the title compound was yielded as white fine powder 
(12.00 g, 37.50 mmol, 75%, m.p. 175 ˚C, literature[77] 180 ˚C).
δH (400 MHz, DMSO-d6) 12.94 (s, br, 1H, NH), 7.79 (s, 1H, NCHN).
HRMS m/z 320.8370. (C3H3N2127I2+ requires 320.8380).
N NH
I I
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Synthesis of 4,5-diiodo-1-(4-methoxybenzyl)-1H-imidazole[78] 
 
61
A mixture of 4,5-diiodo-imidazole 66 (3.20 g, 10 mmol) and sodium hydride (0.40 g, 10 
mmol) were stirred in anhydrous THF (10 mL) at 0 ˚C for 1 hour. PMB-Cl (1.57 g, 10 mmol) 
was then added dropwise wth vigorous string. The reaction mixture was stirred at 55 ˚C for 
12 hours, and then it was cooled to room temperature and quenched with ethanol (2 mL). 
After extration with deionized water (20 mL) and dichloromethane (3 x 20 mL). The organic 
layer was washed with brine and dried over magnesium sulfate. After filtration and 
purification via column chromatography (elution with petroleum ether: ethyl acetate=20: 1) 
the title compound was yielded as white solid (4 g, 9.01 mmol, 91%, m.p. 157 ˚C, 
literature[78] 160 ˚C).
νmax (KBr, cm-1) 3099, 2939, 2832, 1651, 1517, 1481, 1170.
δH (400 MHz, DMSO-d6) 7.55 (s, 1H, NCHN), 7.27 (d, J = 9 Hz, 2H, phenyl), 6.95 (d, J = 9 
Hz, 2H, phenyl), 5.06 (s, 2H, CH2), 3.79 (s, 3H, CH3).
HRMS m/z 440.8954. (C11H11N2O127I2+ requires 440.8956).
N N
I I
O
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Synthesis of ethyl 5-iodo-1-[(4-methyoxyphenyl)methyl]-1H-imidazole-4-carboxylate
 
64
To a dried flask a solution of 4,5-diiodo-1-(4-methoxybenzyl)-1H-imidazole 61 (0.88 g, 2 
mmol) in anhydrous THF (10 mL) was added a solution of Bu-Li (2.5 M, 0.5 mL, 5 mmol) 
diluted with anhydrous THF (2 mL) dropwise under nitrogen protection at -78 ˚C. The 
reaction mixture was warmed to room temperature and stirred for 30 minutes. After cooled 
to -78 ˚C, a solution of ethyl chloroformate (0.17 mL, 2 mmol) in anhydrous THF (10 mL) 
was added fast under nitrogen protection. The reaction mixture was warmed to room 
temperature and left overnight. After the solvent evaporated, the mixture was treated with 
deionized water (20 mL) and extracted with ethyl acetate (20 x 3 mL). The organic layer 
was washed with brine and dried over magnesium sulfate. After filtration and purification 
via column chromatography (elution with petroleum: ethyl acetate=10: 1), the title 
compound was yielded as pale yellow oil (0.62 g, 1.20 mmol, 60%).
δH (400 MHz, DMSO-d6) 7.70 (s, 1H), 7.32 (d, J = 9 Hz, 2H, phenyl), 6.85 (d, J = 9 Hz, 2H, 
phenyl), 5.43 (s, 2H, CH2), 4.36 (quartet, J=7 Hz, 2H, CH2), 3.77 (s, 3H, OCH3), 1.32 (t, J = 
7 Hz, 3H, CH3).
δC (100 MHz, DMSO-d6) 159.9, 158.33, 150.9, 150.2, 136.44, 129.73 (2C, phenyl), 113.5 
(2C, phenyl), 105.3, 62.41 (CH2), 58.64 (CH2), 52.16, 17.3.
HRMS m/z 387.1999. (C14H16127IN2O3+ requires 387.1996). 






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Synthesis of 7-(propan-2-yl)-1-(2,3,5-tri-O-propanoylpentofuranosyl)-1H-imidazo[2,1-
b]purin-4(5H)-one
 
68
A mixture of 2’,3’,5’-tripropanoate-guanosine 49 (4.51 g, 1 mmol) and 1-bromo-3-methyl-
butanone (0.16 g, 1 mmol) was stirred in the presence of sodium hydride (0.08 g, 2 mmol) 
in DMF (4 mL) at 80 ˚C for 12 hours. After the solvent evaporated, the mixture was diluted 
with deionized water (20 mL) and extracted with dichloromethane (20 mL x 3). The organic 
layer was washed with brine and stirred over magnesium sulfate. After filtration and 
purification via column chromatography (elution with methanol: ethyl acetate=1: 10), the 
title compound was yielded as pale yellow liquid (0.12 g, 0.2 mmol, 20%).
δH (400 MHz, CDCl3) 12.15 (s, br, 1H, NH), 7.99 (s, 1H, NCHN), 7.68 (s, 1H, NCHC), 6.22 
(d, J = 6 Hz, 1H, CHN in ribose), 6.01 (t, J = 6 Hz, 1H, CHO in ribose), 5.69 (t, J = 6 Hz, 
1H, CHO in ribose), 4.43-4.32 (m, 3H, OCH2 and CH in ribose), 2.78 (septet, J = 6 Hz, 
1H), 2.37-2.28 (m, 6H, COCH2), 1.25 (d, J = 6 Hz, 6H, CH3), 1.13-1.01 (m, 9H, CH3).
HRMS m/z 512.5022. (C24H26N5O8+ requires 512.5014).
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Synthesis of 7-phenyl-1-(2,3,5-tri-O-propanoylpentofuranosyl)-1H-imidazo[2,1-
b]purin-4(5H)-one
 
69
A mixture of 2’,3’,5’-tripropanoate-guanosine 49 (4.51 g, 1 mmol) and 2-bromo-1-phenyl-
ethanone (0.20 g, 1 mmol) was stirred in the presence of sodium hydride (0.08 g, 2 mmol) 
in DMF (4 mL) at 80 ˚C for 12 hours. After the solvent evaporated, the mixture was diluted 
with deionized water (20 mL) and extracted with dichloromethane (20 mL x 3). The organic 
layer was washed with brine and stirred over magnesium sulfate. After filtration and 
purification via column chromatography (elution with methanol: ethyl acetate=1:10), the 
title compound was yielded as pale yellow liquid (0.07 g, 0.12 mmol, 12%).
δH (400 MHz, CDCl3) 12.26 (s, br, 1H, NH), 8.01 (s, 1H, NCHN), 7.73 (d, J = 6.4 Hz, 2H), 
7.71 (s, 1H, NCHC), 7.48 (t, J = 8 Hz, 1H), 7.42 (t, J = 5.6 Hz, 2H), 6.23 (d, J = 6 Hz, 1H, 
CHN in ribose), 5.99 (t, J = 6 Hz, 1H, CHO in ribose), 5.68 (t, J = 6 Hz, 1H, CHO in ribose), 
4.46-4.36 (m, 3H, OCH2 and CH in ribose), 2.39-2.28 (m, 6H, COCH2), 1.13-1.01 (m, 9H, 
CH3).
HRMS m/z 552.5664. (C27H30N5O8+ requires 552.5661). 
NH
N
N
O
N
O
OO
O
O
O O
N
  / 102 156
Synthesis of 4-isopropyl-2-methyl-1H-imidazole
 
70
To a solution of acetamidine hydrochloride (0.95 g, 10 mmol) and sodium hydride (0.80 g, 
20 mmol) in DMF (4 mL) was added 1-bromo-3-methyl-2-ketone 56 (1.65 g, 10 mmol) 
dropwise.  The reaction mixture was stirred at room temperature for 8 hours. Then it was 
quenched with ethanol (2 mL), and neutralized with 1M HCl till the pH reached slightly 
higher than 7. After extration with deionized water (20 mL) and dichloromethane (3 x 20 
mL), the organic layer were combined, washed with brine and dried over magnesium 
sulfate. After filtration and purification via column chromatography (elution with petroleum 
ether: ethyl acetate=1: 5) the title compound was yielded as yellow oil (0.44 g, 3.50 mmol, 
35%).
δH (400 MHz, DMSO-d6) 7.90 (s, br, 1H, NH), 6.55 (s, 1H, CH), 2.67 (septet, J = 7 Hz, 1H, 
CH), 2.03 (s, 3H, CH3), 1.02 (d, J = 7 Hz, 6H, CH3).
δC (100 MHz, CDCl3) 162.83, 145.32, 114.71, 27.47, 22.29 (2C), 17.35.
HRMS m/z 111.1889. (C7H13N2+ requires 111.1882).
N NH
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Synthesis of 2-methyl-4-phenyl-1H-imidazole[79]
 
71
To a solution of acetamidine hydrochloride (0.95 g, 10 mmol) and sodium hydride (0.80 g, 
20 mmol) in DMF (4 mL) was added 2-bromo-1-phenyl-ethanone (2 g, 10 mmol) dropwise. 
The reaction mixture was stirred at room temperature for 8 hours. Then it was quenched 
with ethanol (2 mL), and neutralized with 1M HCl till the pH reached slightly higher than 7. 
After extration with deionized water (20 mL) and dichloromethane (3 x 20 mL), the organic 
layer were combined, washed with brine and dried over magnesium sulfate. After filtration 
and purification via column chromatography (elution with petroleum ether: ethyl acetate=1: 
5) the title compound was yielded as yellow solid (0.44 g, 2.78 mmol, 28%, m.p. 158 ˚C, 
literature[79] 159 ˚C).
δH (400 MHz, DMSO-d6) 9.53 (s, br, 1H, NH), 7.78 (d, J = 8 Hz, 2H, phenyl), 7.35-7.25 (m, 
3H, phenyl), 6.55 (s, 1H, CH), 2.03 (s, 3H, CH3),
HRMS m/z 159.2070. (C10H11N2+ requires 159.2072).
N NH
  / 104 156
Synthesis of 2-methylthio-4phenyl-1H-imidazole[80]
 
72
To a solution of S-methylisothiourea hemisulfate salt (1.39 g, 10 mmol) and sodium 
hydride (0.80 g, 20 mmol) in DMF (4 mL) was added 1-bromo-3-methyl-butanone (1.60 g, 
10 mmol) dropwise.  The reaction mixture was stirred at room temperature for 8 hours. 
Then it was quenched with ethanol (2 mL), and neutralized with 1M HCl till the pH reached 
slightly higher than 7. After extraction with deionized water (20 mL) and dichloromethane 
(3 x 20 mL), the organic layer were combined, washed with brine and dried over 
magnesium sulfate. After filtration and purification via column chromatography (elution with 
petroleum ether: ethyl acetate=1: 5) the title compound was yielded as yellow solid (0.34 
g, 1.78 mmol, 18%, m.p. 134 ˚C, literature[80] 137 ˚C).
νmax (KBr, cm-1) 3020.
δH (400 MHz, DMSO-d6) 7.80 (d, J = 8 Hz, 2H, phenyl), 7.33 (t, J = 8 Hz, 1H), 7.26 (t, J = 8 
Hz, 2H, phenyl), 6.43 (s, 1H, CH), 2.64 (s, 3H, SCH3).
HRMS m/z 191.2734. (C10H11N232S+ requires 191.2727).
N NH
S
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Section 3: experimental for triazine analogues
Synthesis of 2,4-difluoro-6-(N,N-dimethylaminophenyl)-s-triazine[81]
 
74
A mixture of cyanuric fluoride 73 (1.02 g, 7.5 mmol) and N,N-dimethylaniline (0.88 g, 7 
mmol) was refluxed overnight in acetonitrile (5 mL). On cooling a red solid precipitated 
which was collected by filtration, washed with deionized water and recrystallized from 
acetonitrile to yield the title compound (0.54 g, 2.3 mmol, 33%, m.p. 235 ˚C, literature[81] 
237 ˚C).
δH (400 MHz, CDCl3) 8.34 (dt, J = 9, 2 Hz, 2H, phenyl), 6.70 (dt, J = 9, 2 Hz, 2H, phenyl), 
3.12 (s, 6H, CH3).
δF (376 MHz, CDCl3) -124.77 (s, 2F).
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Preparation of Grignard reagents
Preparation of (2,4-dimethoxyphenyl)-magnesium bromide
 
75
To a dried flask containing a suspension of magnesium powder (0.25 g, 20 mmol) in 
anhydrous THF (10 mL) was added 1-bromo-2,4-dimethoxyl-benzene (1.45 mL, 10 mmol) 
in anhydrous THF  (10 mL) dropwise under nitrogen protection. The mixture was heated 
under reflux for 2 hours and then cooled to room temperature, and used directly in the 
required experiment.
Preparation of (1,3-benzodioxole)-magnesium bromide
 
76
To a dried flask containing a suspension of magnesium powder (0.25 g, 20 mmol) in 
anhydrous THF (10 mL) was added 5-bromo-1,3-benzodioxole (1.17 mL, 10 mmol) in 
anhydrous THF (10 mL) dropwise under nitrogen protection. The mixture was heated 
under reflux for 2 hours and then cooled to room temperature, and used directly in the 
required experiment.
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Synthesis of 2-fluoro-4-(N,N-dimethylaminophenyl)-6-(2,4-dimethoxyphenyl)-s-
triazine
 
77
To a solution of 2,4-difluoro-6-(N,N-dimethylaminophenyl)-s-triazine 74 (0.54 g, 2.3 mmol) 
in anhydrous THF (10 mL) was added a solution of (2,4-dimethoxyphenyl)-magnesium 
bromide 75 in THF (2M, 1 mL, 2 mmol) diluted with anhydrous THF (5 mL) dropwise at 0 
˚C. The reaction was warmed to room temperature and left overnight, and then diluted with 
deionized water (20 mL) and extracted with ethyl acetate (20 x 3 mL). The organic layer 
was washed with brine and dried over magnesium sulfate. After filtration and purification 
via column chromatography (elution with petroleum ether: ethyl acetate=60: 1), the title 
compound was yielded as pale yellow oil (0.15 g, 0.5 mmol, 25%).
δH (400 MHz, CDCl3) 8.44 (d, J = 8 Hz, 2H, phenyl), 8.27 (d, J = 8 Hz, 1H, phenyl), 6.73 
(d, J = 9 Hz, 2H, phenyl), 6.62 (dd, J = 9, 2 Hz, 1H, phenyl), 6.56 (d, J = 2 Hz, 1H, phenyl), 
3.95 (s, 3H, OCH3), 3.88 (s, 3H, OCH3), 3.09 (s, 6H, CH3).
δC (100 MHz, CDCl3) 175.64 (d, J = 66 Hz, CF coupling, 1Ctri-Cphenyl), 171.42 (d, J = 245 
Hz, CF coupling, 1Ctri-F), 165.42 (d, J = 66 Hz, CF coupling, 1Ctri-Cphenyl), 163.45, 159.06, 
154.64, 152.21, 132.5, 131.01 (2C, phenyl), 122.21, 121.25, 111.15 (2C, phenyl), 105.31, 
55.88, 55.64, 40.19 (2C, CH3).
δF (376 MHz, CDCl3) -121.76 (s, 1F)
HRMS m/z 303.3822. (C19H19FN4+ requires 303.3818). 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Synthesis of 2,4-dichloro-6-(2,4-dimethoxyphenyl)-s-triazine
 
79
Method 1:
To a solution of cyanuric chloride 29 (3.84 g, 20 mmol) in anhydrous THF (20 mL) was 
added (2,4-dimethoxyphenyl)-magnesium bromide 75 in THF (2M, 10 mL, 20 mmol) 
dropwise at 0 ℃ under nitrogen protection. The mixture was warmed to room temperature 
and left overnight. The reaction was cooled to 0 ℃ and quenched by addition of saturated 
NH4Cl (10 mL), and then extracted with ethyl acetate (20 mL x 3). The organic layer was 
washed with brine (20 mL) and dried over magnesium sulfate. After filtration and 
purification via column chromatography (elution with petroleum ether: ethyl acetate=30: 1), 
the title compound was yielded as white solid (4.29 g, 15 mmol, 75%, m.p. 125 ˚C).
δH (400 MHz, CDCl3) 8.22 (d, J = 9 Hz, 1H, phenyl), 6.64 (dd, J = 9, 2 Hz, 1H, phenyl), 
6.56 (d, J = 2 Hz, 1H, phenyl), 3.97 (s, 3H, OCH3), 3.93 (s, 3H, OCH3).
MS m/z 286.0140. (C11H1035Cl2N3O2+ requires 286.0145).
Method 2:
To a dried flask containing a solution of 1-bromo-2,4-dimethoxyl-benzene 75 (2M, 1.45 mL, 
10 mmol) in anhydrous THF (10 mL) was added a solution of Bu-Li (2.5 M, 4.4 mL, 11 
mmol) diluted with anhydrous THF (2 mL) dropwise under nitrogen protection at -78 ˚C. 
The reaction mixture was warmed to room temperature and stirred for 30 minutes. After 
cooled to -78 ˚C, a solution of cyanuric chloride 29 (1.92 g, 10 mmol) in anhydrous THF 
(10 mL) was added fast under nitrogen protection. The reaction mixture was warmed to 
room temperature and left overnight. After the solvent evaporated, the mixture was treated 
with deionized water (20 mL) and extracted with ethyl acetate (20 x 3 mL). The organic 
layer was washed with brine and dried over magnesium sulfate. After filtration and 
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purification via column chromatography (elution with petroleum: ethyl acetate=10: 1), the 
title compound was yielded as white solid (4.17 g, 7.3 mmol, 73%).
The product was identified to be the same by comparison (1H NMR) with the compound 
prepared above. 
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Synthesis of 2,4-dichloro-6-(1,3-benzodioxole-5-yl)-s-triazine
 
80
Method 1:
To a solution of cyanuric chloride 29 (3.84 g, 20 mmol) in anhydrous THF (20 mL) was 
added (1,3-benzodioxol-5-yl)-magnesium bromide 76 (2M, 10 mL, 20 mmol) dropwise at 0 
℃ under nitrogen protection. The mixture was warmed to room temperature and left 
overnight. The reaction was cooled to 0 ℃ and quenched by addition of saturated NH4Cl 
(10 mL), then extracted with ethyl acetate (20 mL x 3). The organic layer was washed with 
brine (20 mL) and dried over magnesium sulfate. After filtration and purification via column 
chromatography (elution with petroleum ether: ethyl acetate=60: 1), the title compound 
was yielded as white solid (3.78 g, 14 mmol, 70%, m.p. 138 ˚C).
δH (400 MHz, CDCl3) 8.17 (dd, J = 8, 2 Hz, 1H, Ar-H), 7.90 (d, J= 2 Hz, 1H, phenyl), 6.91 
(d, J = 8 Hz, 1H, phenyl), 6.09 (s, 2H, OCH2O).
δC (100 MHz, CDCl3) 172.12 (2C, Ctri-Cl), 165.49 (1C, Ctri-Cphenyl), 151.58, 147.98, 129.28, 
124.49, 108.63, 108.26, 101.77 (CH2).
HRMS m/z 269.9827. (C10H635Cl2N3O2+ requires 269.9832).
Method 2:
To a dried flask containing a solution of 5-bromo-1,3-benzodioxole 76 (2M, 1.17 mL, 10 
mmol) in anhydrous THF (10 mL) was added a solution of Bu-Li (2.5 M, 4.4 mL, 11 mmol) 
diluted with anhydrous THF (2 mL) dropwise under nitrogen protection at -78 ˚C. The 
reaction mixture was warmed to room temperature and stirred for 30 minutes. After cooled 
to -78 ˚C, a solution of cyanuric chloride (1.92 g, 10 mmol) in anhydrous THF (10 mL) was 
added fast under nitrogen protection. The reaction mixture was warmed to room 
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temperature and left overnight. After the solvent evaporated, the mixture was treated with 
deionized water (20 mL) and extracted with ethyl acetate (20 x 3 mL). The organic layer 
was washed with brine and dried over magnesium sulfate. After filtration and purification 
via column chromatography (elution with petroleum: ethyl acetate=10: 1), the title 
compound was yielded as white solid (3.34 g, 6.2 mmol, 62%).
The product was identified to be the same by comparison (1H NMR) with the compound 
prepared above.
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Synthesis of 2-chloro-4-(1,3-benzodioxole-5-yl)-6-(2,4-dimethoxyphenyl)-s-triazine
 
81
To a dried flask a solution of 5-bromo-1,3-benzodioxole (1.17 mL, 10 mmol) 1-bromo-2,4-
dimethoxyl-benzene (1.45 mL, 10 mmol) in anhydrous THF was added Bu-Li (2.5 M, 4.4 
mL, 11 mmol) in anhydrous THF (10 mL) dropwise under nitrogen protection at -78 ˚C. The 
reaction mixture was warmed to room temperature and stirred for 30 minutes. After cooled 
to -78 ˚C, a solution of 2,4-dichloro-6-(2,4-dimethoxyphen-1-yl)-s-triazine 79 (2.85 g, 10 
mmol) 2,4-dichloro-6-(1,3-benzodioxole-5-yl)-s-triazine 80 (2.70 g, 10 mmol) in anhydrous 
THF (10 mL) was added dropwise under nitrogen protection. The reaction mixture was 
warmed to room temperature and left overnight. After the solvent evaporated, the mixture 
was treated with deionized water (20 mL) and extracted with ethyl acetate (20 x 3 mL). 
The organic layer was washed with brine and dried over magnesium sulfate. After filtration 
and purification via column chromatography (elution with petroleum: ethyl acetate=10: 1), 
the title compound was yielded as yellow oil (1.30 g, 3.5 mmol, 35%).
δH (400 MHz, CDCl3) 8.22 (dd, J = 8, 2 Hz, 1H, phenyl), 8.20 (d, J = 8 Hz, 1H, phenyl), 
8.00 (d, J = 2 Hz, 1H, phenyl), 6.92 (d, J = 8 Hz, 1H, phenyl), 6.61 (dd, J = 8, 2 Hz, 1H, 
phenyl), 6.56 (d, J = 2 Hz, 1H, phenyl), 6.06 (s, 2H, OCH2O), 3.95 (s, 3H, OCH3), 3.88 (s, 
3H, OCH3).
δC (100 MHz, CDCl3) 173.47, 172.16, 171.17, 164.66, 161.59, 152.23, 148.23, 134.58, 
129.09, 125.40, 117.29, 109.12, 108.51, 105.45, 101.95 (CH2), 99.48, 56.25 (-OCH3), 
55.64 (-OCH3).
HRMS m/z 372.0735. (C10H635Cl2N3O2+ requires 372.0746). 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Synthesis of 2-(1,3-benzodioxole-5-yl)-4,6-di-(2,4-dimethoxyphenyl)-s-triazine
 
82
To a dried flask a solution of 1-bromo-2,4-dimethoxyl-benzene (3.19 mL, 22 mmol) in 
anhydrous THF was added Bu-Li (2.5 M, 9.68 mL, 22 mmol) in anhydrous THF (10 mL) 
dropwise under nitrogen protection at -78 ˚C. The reaction mixture was warmed to room 
temperature and stirred for 30 minutes. After cooled to -78 ˚C, a solution of 2,4-dichloro-6-
(1,3-benzodioxole-5-yl)-s-triazine 80 (2.70 g, 10 mmol) in anhydrous THF (10 mL) was 
added dropwise under nitrogen protection. The reaction mixture was warmed to 50  ˚C and 
left overnight. After the solvent evaporated, the mixture was treated with deionized water 
(20 mL) and extracted with ethyl acetate (20 x 3 mL). The organic layer was washed with 
brine and dried over magnesium sulfate. After filtration and purification via column 
chromatography (elution with petroleum: ethyl acetate=10: 1), the title compound was 
yielded as yellow oil (1.41 g, 3 mmol, 30%).
δH (400 MHz, CDCl3) 7.59 (dd, J = 8, 2 Hz, 1H, phenyl), 7.43 (d, J = 2 Hz, 1H, phenyl), 
7.38 (d, J = 8 Hz, 2H, phenyl), 6.78 (d, J = 8 Hz, 1H, phenyl), 6.46 (dd, J = 8, 2 Hz, 2H, 
phenyl), 6.35 (d, J = 2 Hz, 2H, phenyl), 6.00 (s, 2H, OCH2O), 3.80 (s, 6H, CH3), 3.45 (s, 
6H, CH3).
δC (100 MHz, CDCl3) 176.35 (2C, Ctri-Cphenyl), 166.25, 163.26 (2C, phenyl), 159.05 (2C, 
phenyl), 151.92, 147.79, 132.36 (2C, phenyl), 126.73, 125.59, 119.94 (2C, phenyl), 
108.98, 107.96, 104.73 (2C, phenyl), 101.95 (CH2), 98.70 (2C, phenyl), 55.57 (2C, OCH3), 
55.39 (2C, OCH3).
HRMS m/z 474.1654. (C26H24N3O6+ requires 474.1660). 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Synthesis of 2,4-dichloro-6-(4-methyl-1-piperazinyl)-s-triazine[83]
 
83
A mixture of cyanuric chloride 29 (1.84 g, 10 mmol) and 1-methyl-piperazine (1.10 mL, 10 
mmol) was stirred stirred in the presence of potassium carbonate (1.38 g, 10 mmol) in THF 
(10 mL) at room temperature for 8 hours. After the solvent evaporated, the mixture was 
treated with deionized water (20 mL) and extracted with ethyl acetate (20 x 3 mL). The 
organic layer was washed with brine and dried over magnesium sulfate. After filtration and 
purification via column chromatography (elution with petroleum ether: ethyl acetate=20: 1), 
the title compound was yielded colorless oil (1.54 g, 6.20 mmol, 62%). 
δH (400 MHz, CDCl3) 3.98-3.93 (m, 4H, piperazine), 2.23-2.19 (m, 4H, piperazine), 2.03 (s, 
3H, CH3).
HRMS m/z 249.2111. (C8H1235Cl2N5+ requires 249.2105). 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Synthesis of 2,4-dichloro-6-(4-morpholinyl)-s-triazine[84]
 
84
A mixture of cyanuric chloride 29 (1.84 g, 10 mmol) and morpholine (0.86 mL, 10 mmol) 
was stirred stirred in the presence of potassium carbonate (1.38 g, 10 mmol) in THF (10 
mL) at room temperature for 8 hours. After the solvent evaporated, the mixture was treated 
with deionized water (20 mL) and extracted with ethyl acetate (20 x 3 mL). The organic 
layer was washed with brine and dried over magnesium sulfate. After filtration, evaporation 
and purification via column chromatography (elution with petroleum ether: ethyl 
acetate=10: 1), the title compound was yielded colorless oil (1.64 g, 7 mmol, 70%, m.p. 
155 ℃, literature[84] 156 ℃).
δH (400 MHz, CDCl3) 3.87-3.86 (m, 4H, morpholine), 3.73-3.72 (m, 4H, morpholine).
HRMS m/z 236.0677. (C7H935Cl2N4O+ requires 236.0685). 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Synthesis of 2,4-dichloro-6-(4-acetyl-1-piperazinyl)-s-triazine
 
85
A mixture of cyanuric chloride 29 (1.84 g, 10 mmol) and 1-acetyl-piperazine (1.25 mL, 10 
mmol) was stirred stirred in the presence of potassium carbonate (1.38 g, 10 mmol) in THF 
(10 mL) at room temperature for 8 hours. After the solvent evaporated, the mixture was 
treated with deionized water (20 mL) and extracted with ethyl acetate (20 x 3 mL). The 
organic layer was washed with brine and dried over magnesium sulfate. After filtration, 
evaporation and purification via column chromatography (elution with petroleum ether: 
ethyl acetate=20: 1), the title compound was yielded as a colorless oil (1.79 g, 6.49 mmol, 
65%). 
δH (400 MHz, DMSO-d6) 3.77-3.67 (m, 4H, piperazine), 3.52-3.45 (m, 4H, piperazine), 2.00 
(s, 3H, CH3).
HRMS m/z 276.0431. (C9H1235Cl2N5O+ requires 276.0424). 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Synthesis of 2, 4-dichloro-6-(N-cyclopentylamino)-s-triazine
 
86
A mixture of cyanuric chloride 29 (0.92 g, 5 mmol) and cyclopentylamine (0.2 mL, 5 mmol) 
was stirred in the presence of potassium carbonate (0.64 g, 5 mmol) in THF (10 mL) at 
0˚C for 5 hours. After the solvent evaporated, the mixture was treated with deionized water 
(20 mL) and extracted with ethyl acetate (20 x 3 mL). The organic layer was washed with 
brine and dried over magnesium sulfate. After filtration and purification via column 
chromatography (elution with petroleum ether), the title compound was yielded as 
colorless oil (1.10 g, 4.9 mmol, 49%).
νmax (KBr, cm-1) 3335 (N-H), 2218 (C=N), 1221 (C-N in 2˚ amine), 780 (C-Cl).
δH (400 MHz, CDCl3) 5.73 (br, s, 1H, NH), 4.34 (apparent sextet, J = 7 Hz, 1H, CH in 
amine), 2.09-2.04 (m, 2H, CH2 in cyclopentyl), 1.72-1.62 (m, 4H, CH2 in cyclopentyl), 
1.51-1.44 (m, 2H, CH2 in cyclopentyl).
HRMS m/z 233.0358. (C8H1135Cl2N4+ requires 233.0355). 
  / 118 156
Synthesis of 2,4-dichloro-6-(2-oxo-1(4H)-pyridinyl)-s-triazine
 
87
A mixture of cyanuric chloride 29 (1.84 g, 10 mmol) and 2-pyridone (0.95 g, 10 mmol) was 
stirred in the presence of triethylamine (1.39 mL, 10 mmol) in THF (10 mL) at 0 ℃ for 5 
hours. After the solvent evaporated, the mixture was treated with deionized water  (20 mL) 
and extracted with ethyl acetate (20 x 3 mL). The organic layer was washed with brine and 
dried over magnesium sulfate. After filtration and purification via column chromatography 
(elution with petroleum ether: ethyl acetate=20: 1), the title compound was yielded as 
colorless oil (1.32 g, 5.41 mmol, 54%).
δH (400 MHz, CDCl3) 8.38 (d, J = 7 Hz, 1H), 7.86 (t, J = 7 Hz, 1H), 7.31 (t, J = 7 Hz, 1H), 
7.11 (d, J = 7 Hz, 1H).
HRMS m/z 244.9819. (C8H535Cl2N4O+ requires 244.9805).
Another by-product, 2-chloro-4,6-di(2-oxo-1(4H)-pyridinyl)-s-triazine, was also identified as 
colorless oil (0.30 g, 1.00 mmol, 10%).
 
δH (400 MHz, CDCl3) 8.35 (d, J = 7 Hz, 2H), 7.77 (t, J = 7 Hz, 2H), 7.20 (t, J = 7 Hz, 2H), 
7.05 (d, J = 7 Hz, 2H).
HRMS m/z 302.0545. (C13H935ClN5O2+ requires 302.0439).
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Synthesis of 2,4-dichloro-6-(4-oxo-1(4H)-pyridinyl)-s-triazine
 
88
A mixture of cyanuric chloride 29 (1.84 g, 10 mmol) and 4-pyridone (0.95 g, 10 mmol) was 
stirred in the presence of triethylamine (1.39 mL, 10 mmol) in THF (10 mL) at 0 ℃ for 5 
hours. After the solvent evaporated, the mixture was treated with deionized water  (20 mL) 
and extracted with ethyl acetate (20 x 3 mL). The organic layer was washed with brine and 
dried over magnesium sulfate. After filtration and purification via column chromatography 
(elution with petroleum ether: ethyl acetate=1: 1), the title compound was yielded as 
colorless oil (1.37 g, 5.61 mmol, 56%).
δH (400 MHz, CDCl3) 8.27 (d, J = 8 Hz, 2H), 7.31 (d, J = 8 Hz, 2H).
HRMS m/z 244.5811. (C8H535Cl2N4O+ requires 244.9805).
Another by-product, 2-chloro-4,6-di(4-oxo-1(4H)-pyridinyl)-s-triazine, was also identified as 
colorless oil (0.35 g, 1.18 mmol, 12%).
 
δH (400 MHz, CDCl3) 8.51 (d, J = 8 Hz, 4H), 7.24 (d, J = 8 Hz, 4H).
HRMS m/z 302.0394. (C13H935ClN5O2+ requires 302.0439). 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Synthesis of 2-fluoro-4-(N-cyclopentylamino)-6-(N,N-dimethylaminophenyl)-s-
triazine
 
89
A mixture of 2,4-difluoro-6-(2,4-dimethoxyphenyl)-s-triazine 74 (1.17 g, 5 mmol) and 
cyclopentylamine (0.20 mL, 5 mmol) was stirred in the presence of triethylamine (0.70 mL, 
5 mmol) overnight in anhydrous THF (10 mL) at room tempreature. After the solvent 
evaporated, the mixture was treated with deionized water (20 mL) and extracted with ethyl 
acetate (20 x 3 mL). The organic layer was washed with brine and dried over magnesium 
sulfate. After filtration and purification via column chromatography (elution with petroleum 
ether: ethyl acetate=60: 1), the title compound was yielded as a pale yellow colored oil 
(0.75 g, 2.5 mmol, 50%).
νmax (KBr, cm-1) 3330 (N-H), 2215 (C=N), 1330 (C-F), 1214 (C-N in 2˚ amine).
δH (400 MHz, CDCl3) 8.22 (d, J = 8 Hz, 2H, phenyl), 6.67 (d, J = 8 Hz, 2H, phenyl), 5.62 
(br, s, 1H, NH), 4.33 (apparent sextet, J = 6 Hz, 1H, CH in cyclopentyl), 3.06 (s, 6H, CH3), 
2.16-2.02 (m, 2H, CH2 in cyclopentyl), 1.78-1.70 (m, 2H, CH2 in cyclopentyl), 1.68-1.60 (m, 
2H, CH2 in cyclopentyl), 1.56-1.44 (m, 2H, CH2 in cyclopentyl).
δC (100 MHz, CDCl3) 174.46 (d, J = 66 Hz, CF coupling, 1Ctri-Cphenyl), 170.02 (d, J = 245 
Hz, CF coupling, 1Ctri-F), 167.94 (d, J = 66 Hz, CF coupling, 1Ctri-Cphenyl), 153.64, 130.91 
(2C, phenyl), 122.21, 111.12 (2C, phenyl), 52.78, 40.18 (2C, CH3), 33.17 (2C, CH2), 23.81 
(2C, CH2).
δF (376 MHz, CDCl3) -122.96 (s, 1F).
HRMS m/z 302.1755. (C16H21FN5+ requires 302.1776).
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Another by-product, 2,4-di(N-cyclopentylamino)-6-(N,N-dimethylaminophenyl)-s-triazine, 
was also obtained as a pale yellow colored oil (0.30 g, 0.75 mmol, 15%).
 
δH (400 MHz, CDCl3) 8.21 (d, J = 8 Hz, 2H, phenyl), 6.69 (d, J = 8 Hz, 2H, phenyl), 
4.47-4.42 (m, br, 2H, NH), 3.02 (s, 6H, CH3), 4.35 (apparent sextet, J = 6 Hz, 2H, CH in 
cyclopentyl), 2.12-1.96 (m, 4H, CH2 in cyclopentyl), 1.77-1.68 (m, 4H, CH2 in cyclopentyl), 
1.67-1.57 (m, 4H, CH2 in cyclopentyl), 1.54-1.42 (m, 4H, CH2 in cyclopentyl).
δC (100 MHz, CDCl3) 170.2, 166.5 (2C, Ctri-N), 152.77, 129.77 (2C, phenyl), 119.8, 111.27 
(2C, phenyl), 52.56 (2C, CH in cyclopentyl), 40.29 (2C, CH3), 33.41 (4CH2, CH2 in 
cyclopentyl), 23.86 (4CH2, CH2 in cyclopentyl).
HRMS m/z 403.2617. (C21H31N6+ requires 403.2610).  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Synthesis of 2-chloro-4-(N-cyclopentylamino)-6-(2,4-dimethoxyphenyl)-s-triazine
 
90
A mixture of 2,4-dichloro-6-(2, 4-dimethoxyphen-1-yl)-s-triazine 79 (2.85 g, 10 mmol) and 
cyclopentylamine (0.40 mL, 10 mmol) was stirred in the presence of triethylamine (1.53 
mL, 11 mmol) overnight in anhydrous THF (10 mL) at room tempreature. After the solvent 
evaporated, the mixture was treated with deionized water (20 mL) and extracted with ethyl 
acetate (20 x 3 mL). The organic layer was washed with brine and dried over magnesium 
sulfate. After filtration, evaporation and purification via column chromatography (elution 
with petroleum ether: ethyl acetate=30: 1), the title compound was yielded as colorless oil 
(1.50 g, 4.5 mmol, 45%).
νmax (KBr, cm-1) 3340 (NH), 1235 (CO), 1214 (C-N in 2˚ amine).
δH (400 MHz, CDCl3) 7.96 (d, J = 8 Hz, 1H), 6.56 (dd, J = 8, 2 Hz, 1H), 6.54 (d, J = 2 Hz, 
1H), 5.64 (s, br, 1H), 4.40 (apparent sextet, J = 6 Hz, 1H), 3.89 (s, 3H), 3.87 (s, 3H), 
2.12-2.02 (m, 2H), 1.74-1.69 (m, 2H), 1.68-1.62 (m, 2H),1.52-1.42 (m, 2H).
δC (100 MHz, CDCl3) 176.41, 171.32, 164.75, 163.16, 158.95, 152.33, 132.76, 119.66, 
104.53, 56.21, 55.74. 52.72, 40.16 (2C), 33.21 (2CH2), 23.83 (2CH2).
HRMS m/z 335.1258. (C16H2035ClN4O2+ requires 335.1269).
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Another by-product, 2,4-di(N-cyclopentylamino)-6-(2,4-dimethoxyphenyl)-s-triazine, was 
also isolated as colorless oil (0.50g, 1.3 mmol, 13%).
 
νmax (KBr, cm-1) 3300 (NH), 1220 (C-N in 2˚ amine).
δH (400 MHz, CDCl3) 7.96 (d, J = 8 Hz, 1H), 6.54 (dd, J = 8, 2 Hz, 1H), 6.55 (d, J = 2 Hz, 
1H), 5.88 (s, br, 2H), 4.55 (apparent sextet, J = 6 Hz, 2H), 3.89 (s, 3H), 3.87 (s, 3H), 
2.22-2.12 (m, 4H), 1.83-1.71 (m, 4H), 1.69-1.63 (m, 4H),1.52-1.42 (m, 4H).
δC (100 MHz, CDCl3) 174.31, 172.46, 165.11 (2C, Ctri-N), 162.88, 158.78, 152.23, 132.32, 
119.21, 104.33, 56.25 (1C, OCH3), 55.64 (1C, OCH3), 52.51 (2C, CH in cyclopentyl), 33.39 
(4C, CH2 in cyclopentyl), 23.84 (4C, CH2 in cyclopentyl).
HRMS m/z 384.2374. (C21H30N5O2+ requires 384.2394). 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Synthesis of 2-chloro-4-(4-methyl-1-piperazin-1-yl)-6-(2,4-dimethoxyphen-1-yl)-s-
triazine 
 
91
A mixture of 2,4-dichloro-6-(2,4-dimethoxyphen-1-yl)-s-triazine 79 (2.85 g, 10 mmol) and 1-
methylpiperazine (1.10 mL, 10 mmol) was stirred in the presence of potassium carbonate 
(1.38 g, 10 mmol) overnight in anhydrous THF (10 mL) at room temperature. After the 
solvent evaporated, the mixture was treated with deionized water (20 mL) and extracted 
with ethyl acetate (20 x 3 mL). The organic layer was washed with brine and dried over 
magnesium sulfate. After filtration and purification via column chromatography (elution with 
petroleum ethyl acetate), the title compound was yielded as colorless oil (1.40 g, 4 mmol, 
40 %).
δH (400 MHz, CDCl3) 8.10 (d, J = 8 Hz, 1H, phenyl), 6.62 (d, J = 8, 2 Hz, 1H, phenyl), 6.55 
(d, J = 2 Hz, 1H, phenyl), 3.95 (s, 3H, CH3), 3.93 (s, 3H, CH3), 3.55-3.58 (m, 4H, 
piperazine), 3.30-3.33 (m, 4H, piperazine), 2.26 (s, 3H, CH3).
δC (100 MHz, CDCl3) 178.34, 174.36, 168.61, 160.32, 156.61, 133.22, 105.33, 102.27, 
100.00, 56.22, 55.35, 54.59 (2C, CH2), 47.31 (2C, CH2), 46.15.
HRMS m/z 349.8142. (C16H2035ClN5O2+ requires 349.8153). 
  / 125 156
Synthesis of 2-chloro-4-(N-cyclopentylamino)-6-(1,3-benzodioxole-5-yl)-s-triazine
 
92
A mixture of 2, 4-dichloro-6-(1,3-benzodioxole-5-yl)-s-triazine 80 (0.54 g, 2 mmol) and 
cyclopentylamine (0.08 mL, 2 mmol) was stirred in the presence of triethylamine (0.28 mL, 
2 mmol) overnight in anhydrous THF (10 mL) at room temperature. After the solvent 
evaporated, the mixture was treated with deionized water (20 mL) and extracted with ethyl 
acetate (20 x 3 mL). The organic layer was washed with brine and dried over magnesium 
sulfate. After filtration and purification via column chromatography (elution with petroleum 
ether: ethyl acetate=30: 1), the title compound was yielded as colorless oil (0.26 g, 0.82 
mmol, 41%).
νmax (KBr, cm-1) 3340 (NH), 1350 (C-N in 2˚ amine), 790 (C-Cl).
δH (400 MHz, CDCl3) 8.66 (d, J = 8 Hz, 1H, phenyl), 7.87 (dd, J = 8, 2 Hz, 1H, phenyl), 
6.90 (d, J = 8 Hz, 1H, phenyl), 6.07 (s, 2H, OCH2O), 5.61 (br, s, 1H, NH), 4.48 (apparent 
sextet, J=6 Hz, 1H, CH in cyclopentyl), 2.18-2.07 (m, 2H, CH2 in cyclopentyl), 1.82-1.67 
(m, 4H, CH2 in cyclopentyl), 1.60-1.48 (m, 2H, CH2 in cyclopentyl).
δC (100 MHz, CDCl3) 172.06, 170.08, 165.71, 151.69, 147.98, 129.28, 124.89, 108.89, 
108.19, 101.77 (CH2), 53.05 (1C, CH in cyclopentyl), 33.11 (2C, CH2 in cyclopentyl), 23.68 
(2C, CH2 in cyclopentyl).
HRMS m/z 319.0945. (C15H1635ClN4O2+ requires 319.0956). 
  / 126 156
Synthesis of 2-chloro-4-(4-methyl-1-piperazin-1-yl)-6-(1,3-benzodioxole-5-yl)-s-
triazine
 
93
A mixture of 2, 4-dichloro-6-(1,3-benzodioxole-5-yl)-s-triazine 80 (2.70 g, 10 mmol) and 1-
methylpiperazine (1.10 mL, 10 mmol) was stirred in the presence of potassium carbonate 
(1.38 g, 10 mmol) overnight in anhydrous THF (10 mL) at room tempreature. After the 
solvent evaporated, the mixture was treated with deionized water (20 mL) and extracted 
with ethyl acetate (20 x 3 mL). The organic layer was washed with brine and dried over 
magnesium sulfate. After filtration and purification via column chromatography (elution with 
petroleum ethyl acetate), the title compound was yielded as colorless oil (1.34 g, 0.43 
mmol, 43%).
δH (400 MHz, CDCl3) 8.00 (dd, J = 8, 2 Hz, 1H, phenyl), 7.43 (dd, J = 2 Hz, 1H, phenyl), 
6.99 (d, J = 8 Hz, 1H, phenyl), 6.07 (s, 2H, OCH2O), 3.54-3.57 (m, 4H, piperazine), 
3.31-3.34 (m, 4H, piperazine), 2.26 (s, 3H, CH3).
δC (100 MHz, CDCl3) 176.33, 171.26, 168.93, 165.09, 150.22, 147.64, 123.31, 108.61, 
107.89, 101.44 (1C, OCH2O), 55.05 (2C, CH2 in piperazine), 46.37 (2C, CH2 in 
piperazine), 43.10 (1C, CH3)
HRMS m/z 302.1170. (C15H1735ClN5O2+ requires 302.1167). 
  / 127 156
Synthesis of 2-chloro-4-(4-oxo-1(4H)-pyridinyl)-6-(1,3-benzodioxole-5-yl)-s-triazine
 
94
A mixture of 2, 4-dichloro-6-(1,3-benzodioxole-5-yl)-s-triazine 80 (1.35 g, 5 mmol) and 4-
pyridone (0.48 mL, 5 mmol) was stirred in the presence of sodium hydride (0.24 g, 6 
mmol) in anhydrous THF (10 mL) at 0 ˚C. The reaction mixture was heat to reflux and left 
overnight. After the solvent evaporated, the mixture was treated with deionized water (20 
mL) and extracted with ethyl acetate (20 x 3 mL). The organic layer was washed with brine 
and dried over magnesium sulfate. After filtration and purification via column 
chromatography (elution with petroleum ether: ethyl acetate=30: 1), the title compound 
was yielded as grey colored solid (0.66 g, 2 mmol, 40%, m.p. 298 ˚C).
δH (400 MHz, CDCl3) 8.86 (d, J = 8 Hz, 2H, pyridone), 8.10 (dd, J = 8, 2 Hz, 1H, phenyl), 
7.89 (d, J = 2 Hz, 1H, phenyl), 7.07 (d, J = 8 Hz, 1H, phenyl), 6.24 (d, J = 8 Hz, 2H, 
pyridone), 6.12 (s, 2H, OCH2O).
HRMS m/z 329.0107. (C17H1035ClN4O2+ requires 329.0436).
  / 128 156
Another by-product, 2,4-di(4-oxo-1(4H)-pyridinyl)-6-(1,3-benzodioxole-5-yl)-s-triazine, was 
also identified as grey colored solid (0.68 g, 1.75 mmol, 35%, m.p. 308 ˚C).
 
δH (400 MHz, CDCl3) 9.22 (d, J = 8 Hz, 4H, pyridone), 8.41 (dd, J = 8, 2 Hz, 1H, phenyl), 
8.28 (d, J = 2 Hz, 1H, phenyl), 7.19 (d, J = 8 Hz, 1H, phenyl), 6.38 (d, J = 8 Hz, 4H, 
pyridone), 6.24 (s, 2H, OCH2O).
HRMS m/z 394.3166. (C20H10N5O4+ requires 394.3173). 
  / 129 156
Section 4: experimental for anticancer compounds
Synthesis of 2,3,5,6-tetrafluoro-N-cyclopentyl-4-pyridinamine
 
96
A mixture containing pentafluoropyridine (0.52 mL, 5 mmol) and cyclopentylamine (0.49 
mL, 5 mmol) was stirred in the presence of triethylamine (0.70 mL, 5 mmol) in acetonitrile 
(5 mL). The reaction mixture was then stirred at 0 ˚C for 8 hours. After the solvent 
evaporated, the mixture was  diluted with deionized water (20 mL) and extracted with ethyl 
acetate (20 mL x 3). The organic layer was washed with brine and stirred over magnesium 
sulfate. After filtration and purification via column chromatography (elution with petroleum 
ether), the title compound was yielded as pale yellow liquid (0.94 g, 4 mmol, 80%).
δH (400 MHz, CDCl3) 4.44 (br, s, 1H), 4.09 (apparent sextet, J = 6 Hz, 1H), 2.10-2.02 (m, 
2H), 1.76-1.62 (m, 4H), 1.56-1.48 (m, 2H).
δC (100 MHz, CDCl3) 144.34 (dt, J = 236, 16 Hz, 2C), 137.32 (heptet, J = 6 Hz, 1C), 
130.95 (dd, J = 244, 35 Hz, 2C), 56.20, 34.71 (2CH2), 23.74 (2CH2).
δF (376 MHz, CDCl3) -67.25 (m, 2F), -2.55 (m, 2F).
HRMS m/z 235.0862. (C10H11F4N2+ requires 235.0853).
N
HN
F
F
F
F
  / 130 156
Synthesis of 1-methyl-4-(4-nitrophenyl)-piperazine[20]
 
39
A mixture containing 1-methylpiperazine (2.21 mL, 20 mmol) and 1-fluoro-4-nitrobenzene 
(2.12 mL, 20 mmol) was stirred in the presence of triethylamine (2.80 mL, 20 mmol) 
overnight in acetonitrile (10 mL) at 82 ˚C. After the solvent evaporated, the mixture was 
diluted with deionized water (20 mL) and extracted with dichloromethane (20 mL x 3). The 
organic layer was washed with brine and stirred over magnesium sulfate. After filtration 
and recrystallization from acetonitrile the title compound was yielded as pale yellow solid 
(3.98 g, 18 mmol, 90%, m.p. 103 ˚C, literature[20] 104 ˚C).
δH (400 MHz, CDCl3) 8.11 (d, J = 9 Hz, 2H), 6.81 (d, J = 9 Hz, 2H), 3.43 (t, J = 5 Hz, 4H), 
2.55 (t, J = 5 Hz, 4H), 2.35 (s, 3H).
δC (100 MHz, CDCl3) 154.90, 138.55, 126.04 (2C), 112.78 (2C), 54.61 (2C, CH2), 47.04 
(2C, CH2), 46.14.
NO2
N
N
  / 131 156
Synthesis of 1-(4-aminophenyl)-4-methylpiperazine[20]
 
40
1-Methyl-4-(4-nitrophenyl)-piperazine (1.10 g, 5 mmol) in HPLC grade methanol (150 mL) 
and hydrogen gas were pumped through Pd/C in H cube overnight at 20˚C. After drying 
and purification via column chromatography (elution with methanol: ethyl acetate=1 : 40), 
the title compound was yielded as pale yellow solid (0.96 g, 5 mmol, 99%, m.p. 92˚C, 
literature[20] 94 ˚C)
δH (400 MHz, CDCl3) 8.17 (d, J = 9 Hz, 2H), 6.81 (d, J = 9 Hz, 2H), 3.43 (t, J = 5 Hz, 4H), 
2.55 (t, J = 5 Hz, 4H), 2.35 (s, 3H). NH2 not observed in the spectrum.
δC (100 MHz, CDCl3) 154.91, 138.55, 126.03 (2C), 112.78 (2C), 54.60 (2CH2), 47.05 
(CH2), 46.14.
NH2
N
N
  / 132 156
Synthesis of 1-acetyl-4-(4-nitrophenyl)-piperazine[86]
 
102
A mixture containing 1-acetylpiperazine (1.60 g, 12.5 mmol) and 1-fluoro-4-nitrobenzene 
(1.06 mL, 10 mmol) was stirred in the presence of triethylamine (1.40 mL, 10 mmol) in 
acetonitrile (5 mL) at 82˚C for 8 hours. After the solvent was evaporated, the mixture was 
diluted with deionized water (20 mL) and extracted with dichloromethane (20 mL x 3). The 
organic layer was washed with brine and stirred over magnesium sulfate. After filtration, 
evaporation and recrystallization from acetonitrile the title compound was yielded as pale 
yellow solid (2.49g, 10 mmol, 99%, m.p. 149 ˚C, literature[86] 150 ˚C).
δH (400 MHz, CDCl3) 8.14 (d, J = 9 Hz, 2H), 6.82 (d, J = 9 Hz, 2H), 3.79 (t, J = 5 Hz, 2H), 
3.66 (t, J = 5 Hz, 2H), 3.45 (d, J = 5 Hz, 4H), 2.15 (s, 3H).
δC (100 MHz, CDCl3) 169.24, 154.47, 139.21, 126.06 (2C), 113.06 (2C), 47.08 (CH2), 
46.96 (CH2), 45.55 (CH2), 40.79 (CH2), 21.43. 
NO2
N
N
O
  / 133 156
Synthesis of 4-(4-acetylpiperazin-1-yl)-aniline[86]
 
101
1-Acetyl-4-(4-nitrophenyl)-piperazine (1.25 g, 5 mmol) in HPLC grade methanol (150 mL) 
and hydrogen gas were pumped through Pd/C in an H cube overnight at 20 ˚C. After 
evaporation and purification via column chromatography (elution with methanol: ethyl 
acetate=1: 40), the title compound was yielded as pale yellow solid (1.07 g, 5 mmol, 99%, 
m.p. 131 ˚C, literature[86] 130 ˚C).
δH (400 MHz, DMSO-d6) 6.62 (d, J = 9 Hz, 2H), 6.45 (d, J = 9 Hz, 2H), 4.59 (s, br, 2H), 
3.48 (t, J = 5 Hz, 4H), 2.84 (t, J = 5 Hz, 2H), 2.77 (t, J = 5.2 Hz, 2H), 1.98 (s, 3H).
δC (100 MHz, CDCl3) 169.06, 143.96, 141.02, 119.41 (2C), 116.25 (2C), 51.67 (CH2), 
51.26 (CH2), 46.54 (CH2), 41.63 (CH2), 21.46.
HRMS m/z 220.1452. (C12H18N3O+ requires 220.1444).
NH2
N
N
O
  / 134 156
2,3,5,6-tetrafluoro-N-4-(4-methyl-1-piperazinyl)phenyl-4-pyridinamine
 
103
A mixture containing pentafluoropyridine (0.52 mL, 5 mmol) and 1-(4-aminophenyl)-4-
methylpiperazine (0.96 g, 5 mmol) was stirred in the presence of triethylamine (0.70 mL, 5 
mmol) in acetonitrile (10 mL). The reaction mixture was then stirred at 0 ˚C for 8 hours. 
After the solvent evaporated, the mixture was  diluted with deionized water (20 mL) and 
extracted with ethyl acetate (20 mL x 3). The organic layer was washed with brine and 
stirred over magnesium sulfate. After filtration and purification via column chromatography 
(elution with petroleum ether), the title compound was yielded as white colored solid (1.19 
g, 3.5 mmol, 70%, m.p. 168 ˚C).
δH (400 MHz, CDCl3) 7.05 (d, J = 9 Hz, 2H), 6.88 (d, J = 9 Hz, 2H), 6.25 (s, br, 1H), 3.20 (t, 
J = 5 Hz, 4H), 2.57 (t, J = 5 Hz, 4H), 2.34 (s, 3H). NH not shown in spectrum.
δC (100 MHz, CDCl3) 149.72, 144.33 (d, J = 245 Hz, 2C), 135.42 (m, 1C), 134.2 (d, J = 
250 Hz, 2C), 129.86, 124.6 (2C), 116.18 (2C), 55.12 (2C, CH2), 49.08 (2C, CH2), 46.23.
δF (376 MHz, CDCl3) -159.53 (m, 2F), -94.56 (m, 2F).
HRMS m/z 341.1397. (C16H17F4N4+ requires 341.1384). 
N
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  / 135 156
Synthesis of 2,3,5,6-tetrafluoro-N-4-(4-acetyl-1-piperazinyl)phenyl-4-pyridinamine
 
104
A mixture containing pentafluoropyridine (1.04 mL, 10 mmol) and 4-(4-acetylpiperazin-1-
yl)-aniline (2.14 g, 10 mmol) was stirred in the presence of triethylamine (1.40 mL, 10 
mmol) in acetonitrile (20 mL). The reaction mixture was then stirred at 0˚C for 8 hours. 
After the solvent evaporated, the mixture was  diluted with deionized water (20 mL) and 
extracted with ethyl acetate (20 mL x 3). The organic layer was washed with brine and 
stirred over magnesium sulfate. After filtration and purification via column chromatography 
(elution with petroleum ether), the title compound was yielded as white colored solid (2.76 
g, 7.5 mmol, 75%, m.p. 194 ˚C).
δH (400 MHz, CDCl3) 7.07 (d, J = 9 Hz, 2H), 6.89 (d, J = 9 Hz, 2H), 6.24 (s, br, 1H), 3.77 (t, 
J = 5 Hz, 2H), 3.62 (t, J = 5 Hz, 2H), 3.16 (dt, J = 15, 5 Hz, 4H), 2.14 (s, 3H).
δC (100 MHz, CDCl3) 169.14, 149.23, 144.33 (d, J = 240, 2C), 141.33, 135.21 (d, J = 242, 
2C), 132.70 (m, 1C), 124.49 (2C), 116.89 (2C), 49.72 (CH2), 49.39 (CH2), 46.23 (CH2), 
41.53 (CH2), 21.45.
δF (376 MHz, CDCl3) -68.96 (m, 2F), -4.17 (m, 2F).
HRMS m/z 369.1341. (C17H17F4N4O+ requires 369.1333).
N
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  / 136 156
Synthesis of N-cyclopentyl-4-methyl-benzenesulfonamide[87]
 
105
p-Toluensulfonyl chloride (3.81 g, 20 mmol) in pyridine (2.5 mL) were added to a diluted 
solution of cyclopentylamine (1.95 mL, 20 mmol) and potassium carbonate (5.52 g, 40 
mmol) in dichloromethane (10 mL) drowsily. The reaction mixture was then stirred at 0˚C 
for 8 hours. The product was then extracted with dichloromethane (3 x 20mL). The organic 
layer was washed with brine and stirred over magnesium sulfate. After filtration and 
purification via column chromatography (elution with petroleum ether), the title compound 
as white fine powder (3.23 g, 13.5 mmol, 67.5%, m.p. 82 ˚C, literature[87] 83 ˚C).
δH (400 MHz, CDCl3) 7.76 (d, J = 8 Hz, 2H), 7.27 (d, J = 8 Hz, 2H), 4.97 (s, br, 1H), 3.53 
(apparent sextet, J = 6 Hz, 1H), 2.34 (s, 3H), 1.76-1.67 (m, 2H), 1.63-1.53 (m, 2H), 
1.49-1.40 (m, 2H), 1.39-1.29 (m, 2H).
HRMS m/z 240.1052. (C12H18NO2S+ requires 240.1053). 
HN
S
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  / 137 156
Synthesis of 4-methyl-N-[4-(4-methylpiperazin-1-yl)phenyl]benzene-1-sulfonamide
 
106
p-Toluensulfonyl chloride (0.95 g, 5 mmol) in pyridine (2.5 mL) were added to a diluted 
solution of 1-(4-aminophenyl)-4-methylpiperazine (0.96 g, 5 mmol) and potassium 
carbonate (1.38 g, 10 mmol) in dichloromethane (10 mL) dropwise. The reaction mixture 
was then stirred at 0 ˚C for 8 hours. The product was then extracted with dichloromethane 
(3 x 20mL). The organic layer was washed with brine and stirred over magnesium sulfate. 
After filtration and purification via column chromatography (elution with petroleum ether), 
the title compound was obtained as yellow oil (1.24 g, 3.6 mmol, 72%).
δH (400 MHz, CDCl3) 7.57 (d, J = 7 Hz, 2H), 7.18 (d, J = 7 Hz, 2H), 6.94 (d, J = 9 Hz, 2H), 
6.74 (d, J = 9 Hz, 2H), 3.19 (t, J = 5 Hz, 4H), 2.69 (t, J = 5 Hz, 4H), 2.43 (s, 3H), 2.35 (s, 
3H). NH not observed in the spectrum.
δC (100 MHz, CDCl3) 162.45, 143.15, 133.42, 133.25, 129.36 (2C), 127.15(2C), 123.89 
(2C), 114.77 (2C), 55.78 (2CH2), 48.08 (2CH2), 46.17, 23.1.
HRMS m/z 346.1595. (C18H24N3O2S+ requires 346.1584). 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  / 138 156
Synthesis of N-cyclopentyl-4-methyl-N-(2,3,5,6-tetrafluoropyridin-4-yl)benzene-1-
sulfonamide
 
107
A mixture containing pentafluoropyridine (1.58 mL, 15 mmol) and N-cyclopentyl-4-methyl-
benzenesulfonamide (3.23 g, 13.5 mmol) was stirred in the presence of potassium 
carbonate (2.76 g, 20 mmol) in acetonitrile (20 mL). The reaction mixture was then stirred 
at 0˚C for 8 hours. After the solvent evaporated, the mixture was  diluted with deionized 
water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic layer was washed 
with brine and stirred over magnesium sulfate. After filtration and purification via column 
chromatography (elution with petroleum ether), the title compound was yielded as pale 
yellow solid (4.19 g, 11 mmol, 80%).
δH (400 MHz, CDCl3) 7.74 (d, J = 8 Hz, 2H), 7.29 (d, J = 8 Hz, 2H), 3.57 (quintet, J = 6 Hz, 
1H), 2.42 (s, 3H), 1.81-1.72 (m, 2H), 1.65-1.55 (m, 2H), 1.54-1.42 (m, 2H), 1.37-1.28 (m, 
2H).
δC (100 MHz, CDCl3) 144.32 (d, J = 252 Hz, 2C), 143.37, 137.86, 136.25 (m, 1C), 132.45 
(d, J = 255 Hz, 2C), 127.75 (2C), 127.21 (2C), 55.23, 33.59 (2CH2), 23.23 (2CH2), 21.65.
δF (376 MHz, CDCl3) -57.3 (m, 2F), -5.80 (m, 2F).
HRMS m/z 375.3786. (C17H17F4NO2S+ requires 375.3824).
N
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  / 139 156
Synthesis of N-cyclopentyl-propanamide
 
108
A mixture containing propionic anhydride (10.0 ml, 0.10 mmol) and cyclopentylamine (0.98 
mL, 10 mmol) was stirred in the presence of potassium carbonate (2.76 g, 20 mmol) in 
dichloromethane (5 mL) at 0 ˚C under nitrogen protection. The reaction mixture was stirred 
for 2 hours. After the solvent evaporated, the mixture was washed with brine and stirred 
over magnesium sulfate. After filtration, the solvent was evaporated and the title compound 
was yielded as colorless liquid (1.34 g, 9.5 mmol, 95%).
νmax (KBr, cm-1) 3325 (NH), 1565 (CO).
δH (400 MHz, CDCl3) 5.34 (s, br, 1H), 4.18 (heptet, J = 6 Hz, 1H), 2.15 (quartet, J = 7 Hz, 
2H), 1.99-1.93 (m, 2H), 1.68-1.53 (m, 4H), 1.36-1.29 (m, 2H), 1.12 (t, J = 7 Hz, 3H).
HRMS m/z 142.2154. (C8H16NO+ requires 142.2182). 
HN
O
  / 140 156
Synthesis of N-[4-(4-methyl-1-piperazinyl)phenyl]-propanamide
 
109
Propionic anhydride (3.88 mL, 30 mmol) in pyridine (0.25 mL) were added to a diluted 
solution of 1-(4-aminophenyl)-4-methylpiperazine (5.87 g, 31 mmol) and potassium 
carbonate (8.28 g, 60 mmol) in dichloromethane (20 mL) dropwise under nitrogen 
protection. The reaction mixture was then stirred at 0 ˚C for 8 hours. The product was then 
extracted with dichloromethane (3 x 20mL). The organic layer was washed with brine and 
stirred over magnesium sulfate. After filtration, the solvent was evaporated and the title 
compound was obtained as pale yellow solid (6.68 g, 27 mmol, 90%, m.p. 218 ˚C).
δH (400 MHz, CDCl3) 7.38 (d, J = 8 Hz, 2H), 7.02 (s, br, 1H), 6.88 (d, J = 8 Hz, 2H), 
3.18-3.16 (m, 4H), 2.63-2.60 (m, 4H), 2.34 (s, 3H), 2.35 (quartet, J = 7 Hz, 2H), 1.23 (t, J = 
7 Hz, 3H).
δC (100 MHz, CDCl3) 171.80, 148.21, 130.57, 121.33 (2C), 116.80 (2C), 54.94 (2CH2), 
49.44 (2CH2), 45.95, 30.70 (CH2), 9.87.
HRMS m/z 248.1754. (C14H22N3O+ requires 248.1757).
HN
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  / 141 156
Synthesis of N-cyclopentyl-N-(2,3,5,6-tetrafluoropyridin-4-yl)propanamide
 
110
A mixture containing pentafluoropyridine (1.58 mL, 15 mmol) and N-cyclopentyl-
propanamide (2.12 g, 15 mmol) were stirred in the presence of sodium hydride (0.60 g, 15 
mmol) in dichloromethane (20 mL). The reaction mixture was then stirred at 0 ˚C for 8 
hours. After the solvent evaporated, the mixture was  diluted with deionized water (20 mL) 
and extracted with dichloromethane (20 mL x 3). The organic layer was washed with brine 
and stirred over magnesium sulfate. After filtration and purification via column 
chromatography (elution with petroleum ether), the title compound was yielded as pale 
yellow solid (0.94 g, 11.7 mmol, 78%, m.p. 287 ˚C).
δH (400 MHz, CDCl3) 5.35 (br, 1H), 4.20 (apparent sextet, J = 6 Hz, 1H), 2.15 (quartet, J = 
7 Hz, 2H), 2.23-1.94 (m, 2H), 1.68-1.56 (m, 4H), 1.37-1.30 (m, 2H), 1.13 (t, J = 7 Hz, 3H).
δC (100 MHz, CDCl3) 143.98 (d, J = 248 Hz, 2C), 142.54, 135.44 (m, 1C), 131.55 (d, J = 
245 Hz, 2C), 55.15, 33.85 (2C, CH2), 31.55 (CH2), 23.15 (2C, CH2), 9.68.
δF (376 MHz, CDCl3) -63.86 (m, 2F), -7.85 (m, 2F).
HRMS m/z 291.1138. (C13H15F4N2O+ requires 291.1118).
N
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  / 142 156
Synthesis of N-[4-(4-methylpiperazin-1-yl)phenyl]-N-(2,3,5,6-tetrafluoropyridin-4-
yl)propanamide
 
111
A mixture containing pentafluoropyridine (1.58 mL, 15 mmol) and N-[4-(4-methyl-1-
piperazinyl)phenyl]-propanamide （3.71 g, 15 mmol) were stirred in the presence of 
triethylamine (2.10 mL, 15 mmol) in acetonitrile (10 mL). The reaction mixture was then 
stirred at 0˚C for 8 hours. After the solvent evaporated, the mixture was  diluted with 
deionized water (20 mL) and extracted with ethyl acetate (20 mL x 3). The organic layer 
was washed with brine and stirred over magnesium sulfate. After filtration and purification 
via column chromatography (elution with petroleum ether), the title compound was yielded 
as white colored solid (4.46 g, 11.2 mmol, 75%, m.p. 246 ˚C).
δH (400 MHz, CDCl3) 7.37 (d, J = 8 Hz, 2H), 6.88 (d, J = 8 Hz, 2H), 3.16-3.14 (m, 4H), 
2.58-2.55 (m, 4H), 2.35 (quintet, J = 7 Hz, 2H), 2.33 (s, 3H), 1.24 (t, J = 7 Hz, 3H).
δC (100 MHz, CDCl3) 171.82, 148.11, 144.53 (d, J = 242 Hz, 2C), 137.44 (m, 1C), 130.95 
(d, J = 246 Hz, 2C), 130.59, 121.28 (2C), 116.65 (2C), 55.09 (2C, CH2), 49.54 (2C, CH2), 
46.13, 30.62 (CH2), 9.57.
δF (376 MHz, CDCl3) -80.36 (m, 2F), -43.26 (m, 2F).
HRMS m/z 397.3887. (C19H21F4N4O+ requires 397.3893). 
N
N
F
F
F
F
N
N
O
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Synthesis of N-[2-(cyclopentylideneamino)ethyl]aniline
 
114
N-Pheylethylenediamine (1.31 mL, 10 mmol) and cyclopentanone (0.88 g, 10 mmol) was 
stirred in dichloromethane (40 mL) in the presence of magnesium sulphate (4.00 g) at 
room temperature for 8 hours. After filtration, the solvent was evaporated and the title 
compound was as pale yellow liquid (1.43 g, 7.00 mmol, 70%).
δH (400 MHz, CDCl3) 7.19-7.12 (m, 2H), 6.70-6.65 (m, 1H), 6.64-6.61 (m, 2H), 4.10 (s, br, 
1H), 3.17 (t, J = 5 Hz, 2H), 2.87 (t, J = 5 Hz, 2H), 1.83-1.70 (m, 4H), 1.63-1.54 (m, 2H), 
1.35-1.25 (m, 2H).
 
H
N
N
  / 144 156
Synthesis of N1-cyclopentyl-N2-phenyl-1,2-ehanediamine
 
112
A mixture containing N-[2-(cyclopentylideneamino)ethyl]aniline (2.53 g, 12.3 mmol) and 
sodium borohydride (0.49 g, 13 mmol) was stirred in ethanol (30 mL) at room temperature 
for 8 hours. The mixture was  diluted with deionized water (20 mL) and extracted with ethyl 
acetate (20 mL x 3). The organic layer was washed with brine and stirred over magnesium 
sulfate. After filtration, the solvent was evaporated and the title compound was yielded as 
pale yellow liquid (1.90 g, 9.40 mmol, 76%).
δH (400 MHz, CDCl3) 7.18 (t, J = 8 Hz, 2H), 6.71 (t, J = 8 Hz, 1H), 6.64 (d, J = 8 Hz, 2H), 
4.11 (s, br, 1H), 3.21 (t, J = 5 Hz, 2H), 3.08 (apparent sextet, J = 6 Hz, 1H), 2.85 (t, J = 5 
Hz, 2H), 1.90-1.81 (m, 2H), 1.75-1.65 (m, 2H), 1.60-1.50 (m, 2H), 1.38-1.28 (m, 2H).
δC (100 MHz, CDCl3) 150.45, 132.44 (2C), 118.08, 114.65 (2C), 59.76, 47.55 (CH2), 45.05 
(CH2),  33.12 (2C, CH2), 24.22 (2C, CH2).
HRMS m/z 205.1701. (C13H21N2+ requires 205.1699). 
H
N
NH
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Synthesis of N1-cyclopentyl-N2-phenyl-N1-(2,3,5,6-tetrafluoropyridin-4-yl)ethane-1,2-
diamine
 
115
A mixture containing pentafluoropyridine (0.52 mL, 5 mmol) and N1-cyclopentyl-N2-
phenyl-1,2-ehanediamine (1.02 g, 5 mmol) was stirred in the presence of sodium hydride 
(0.60 g, 15 mmol) in dichloromethane (20 mL). The reaction mixture was then stirred at 
0˚C for 8 hours. After the solvent evaporated, the mixture was  diluted with deionized water 
(20 mL) and extracted with dichloromethane (20 mL x 3). The organic layer was washed 
with brine and stirred over magnesium sulfate. After filtration and purification via column 
chromatography (elution with petroleum ether), the title compound was yielded as white 
solid (1.27 g, 35 mmol, 70%, m.p. 162 ˚C).
δH (400 MHz, CDCl3) 9.48 (s, br, 1H), 7.24-7.18 (m, 2H), 6.79-6.76 (m, 3H), 3.65 (t, J = 6 
Hz, 2H), 3.43-3.34 (m, 1H), 3.23 (t, J = 6 Hz, 2H), 2.09-2.00 (m, 2H), 1.94-1.80 (m, 4H), 
1.64-1.51 (m, 2H).
δC (100 MHz, CDCl3) 151.64, 150.45, 144.12 (d, J = 248 Hz, 2C), 135.43 (m, 1C), 130.45 
(d, J = 250 Hz, 2C), 129.27 (2C), 117.94, 116.73 (2C), 59.05, 46.55 (2C, CH2), 45.44 (2C, 
CH2), 35.85 (2C, CH2), 23.15 (2C, CH2).
δF (376 MHz, CDCl3) -90.67 (m, 2F), -20.45 (m, 2F).
HRMS m/z 354.1572. (C18H20F4N3+ requires 354.1588).
N
N
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